1
|
Bannell TAK, Cockburn JJB. The molecular structure and function of fibrocystin, the key gene product implicated in autosomal recessive polycystic kidney disease (ARPKD). Ann Hum Genet 2024; 88:58-75. [PMID: 37905714 DOI: 10.1111/ahg.12535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Revised: 09/14/2023] [Accepted: 10/03/2023] [Indexed: 11/02/2023]
Abstract
Autosomal recessive polycystic kidney disease is an early onset inherited hepatorenal disorder affecting around 1 in 20,000 births with no approved specific therapies. The disease is almost always caused by variations in the polycystic kidney and hepatic disease 1 gene, which encodes fibrocystin (FC), a very large, single-pass transmembrane glycoprotein found in primary cilia, urine and urinary exosomes. By comparison to proteins involved in autosomal dominant PKD, our structural and molecular understanding of FC has lagged far behind such that there are no published experimentally determined structures of any part of the protein. Bioinformatics analyses predict that the ectodomain contains a long chain of immunoglobulin-like plexin-transcription factor domains, a protective antigen 14 domain, a tandem G8-TMEM2 homology region and a sperm protein, enterokinase and agrin domain. Here we review current knowledge on the molecular function of the protein from a structural perspective.
Collapse
Affiliation(s)
- Travis A K Bannell
- Astbury Centre for Structural and Molecular Biology, University of Leeds, Leeds, UK
- School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK
| | - Joseph J B Cockburn
- Astbury Centre for Structural and Molecular Biology, University of Leeds, Leeds, UK
- School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK
| |
Collapse
|
2
|
Lucchetti L, Chinali M, Emma F, Massella L. Autosomal dominant and autosomal recessive polycystic kidney disease: hypertension and secondary cardiovascular effect in children. Front Mol Biosci 2023; 10:1112727. [PMID: 37006611 PMCID: PMC10064450 DOI: 10.3389/fmolb.2023.1112727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Accepted: 02/24/2023] [Indexed: 03/12/2023] Open
Abstract
Autosomal dominant (ADPKD) and autosomal recessive (ARPKD) polycystic kidney disease are the most widely known cystic kidney diseases. They are significantly different from each other in terms of genetics and clinical manifestations. Hypertension is one of the main symptoms in both diseases, but the age of onset and secondary cardiovascular complications are significantly different. Most ARPKD children are hypertensive in the first year of life and need high doses of hypertensive drugs. ADPKD patients with a very early onset of the disease (VEOADPKD) develop hypertension similarly to patients with ARPKD. Conversely, a significantly lower percentage of patients with classic forms of ADPKD develops hypertension during childhood, although probably more than originally thought. Data published in the past decades show that about 20%–30% of ADPKD children are hypertensive. Development of hypertension before 35 years of age is a known risk factor for more severe disease in adulthood. The consequences of hypertension on cardiac geometry and function are not well documented in ARPKD due to the rarity of the disease, the difficulties in collecting homogeneous data, and differences in the type of parameters evaluated in different studies. Overall, left ventricular hypertrophy (LVH) has been reported in 20%–30% of patients and does not always correlate with hypertension. Conversely, cardiac geometry and cardiac function are preserved in the vast majority of hypertensive ADPKD children, even in patients with faster decline of kidney function. This is probably related to delayed onset of hypertension in ADPKD, compared to ARPKD. Systematic screening of hypertension and monitoring secondary cardiovascular damage during childhood allows initiating and adapting antihypertensive treatment early in the course of the disease, and may limit disease burden later in adulthood.
Collapse
Affiliation(s)
- L. Lucchetti
- Division of Nephrology, Department of Paediatric Subspecialties, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
| | - M. Chinali
- Department of Cardiac Surgery, Cardiology and Heart Lung Transplant, Bambino Gesù Children’s Hospital (IRCCS), Rome, Italy
| | - F. Emma
- Division of Nephrology, Department of Paediatric Subspecialties, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
| | - L. Massella
- Division of Nephrology, Department of Paediatric Subspecialties, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
- *Correspondence: L. Massella,
| |
Collapse
|
3
|
Genetic Kidney Diseases (GKDs) Modeling Using Genome Editing Technologies. Cells 2022; 11:cells11091571. [PMID: 35563876 PMCID: PMC9105797 DOI: 10.3390/cells11091571] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Revised: 04/29/2022] [Accepted: 05/04/2022] [Indexed: 02/05/2023] Open
Abstract
Genetic kidney diseases (GKDs) are a group of rare diseases, affecting approximately about 60 to 80 per 100,000 individuals, for which there is currently no treatment that can cure them (in many cases). GKDs usually leads to early-onset chronic kidney disease, which results in patients having to undergo dialysis or kidney transplant. Here, we briefly describe genetic causes and phenotypic effects of six GKDs representative of different ranges of prevalence and renal involvement (ciliopathy, glomerulopathy, and tubulopathy). One of the shared characteristics of GKDs is that most of them are monogenic. This characteristic makes it possible to use site-specific nuclease systems to edit the genes that cause GKDs and generate in vitro and in vivo models that reflect the genetic abnormalities of GKDs. We describe and compare these site-specific nuclease systems (zinc finger nucleases (ZFNs), transcription activator-like effect nucleases (TALENs) and regularly clustered short palindromic repeat-associated protein (CRISPR-Cas9)) and review how these systems have allowed the generation of cellular and animal GKDs models and how they have contributed to shed light on many still unknown fields in GKDs. We also indicate the main obstacles limiting the application of these systems in a more efficient way. The information provided here will be useful to gain an accurate understanding of the technological advances in the field of genome editing for GKDs, as well as to serve as a guide for the selection of both the genome editing tool and the gene delivery method most suitable for the successful development of GKDs models.
Collapse
|
4
|
Long-term kidney and liver outcome in 50 children with autosomal recessive polycystic kidney disease. Pediatr Nephrol 2021; 36:1165-1173. [PMID: 33165639 DOI: 10.1007/s00467-020-04808-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/01/2020] [Revised: 09/10/2020] [Accepted: 10/01/2020] [Indexed: 02/02/2023]
Abstract
BACKGROUND Autosomal recessive polycystic kidney disease (ARPKD) is a rare ciliopathy characterized by congenital hepatic fibrosis and cystic kidney disease. Lack of data about long-term follow-up makes it difficult to discuss timing and type of organ transplantation. Our objectives were to evaluate long-term evolution and indications for transplantation, from birth to adulthood. METHODS Neonatal survivors and patients diagnosed in postnatal period with ARPKD between 1985 January and 2017 December from 3 French pediatric centers were retrospectively enrolled in the study. RESULTS Fifty patients with mean follow-up 12.5 ± 1 years were enrolled. ARPKD was diagnosed before birth in 24%, and at mean age 1.8 years in others. Thirty-three patients were < 1 year of age at first symptoms, which were mostly kidney-related. These most often presented high blood pressure during follow-up. Portal hypertension was diagnosed in 29 patients (58%), 4 of them with bleeding from esophageal varices. Eight patients presented cholangitis (> 3 episodes in three children). Liver function was normal in all patients. Nine children received a kidney transplant without liver complications. A 20-year-old patient received a combined liver-kidney transplant (CLKT) for recurrent cholangitis, and a 15-year-old boy an isolated liver transplant for uncontrollable variceal bleeding despite portosystemic shunt. CONCLUSIONS Long-term outcome in patients with ARPKD is heterogeneous, and in this cohort did not depend on age at diagnosis except for blood pressure. Few patients required liver transplantation. Indications for liver or combined liver-kidney transplantation were limited to recurrent cholangitis or uncontrollable portal hypertension. Liver complications after kidney transplantation were not significant.
Collapse
|
5
|
Franchi F, Peterson KM, Quandt K, Domnick D, Kline TL, Olthoff M, Parvizi M, Tolosa EJ, Torres VE, Harris PC, Fernandez-Zapico ME, Rodriguez-Porcel MG. Impaired Hedgehog-Gli1 Pathway Activity Underlies the Vascular Phenotype of Polycystic Kidney Disease. Hypertension 2020; 76:1889-1897. [PMID: 33012205 DOI: 10.1161/hypertensionaha.120.15483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Polycystic kidney disease (PKD) has been linked to abnormal structure/function of ciliary proteins, leading to renal dysfunction. Recently, attention has been focused in the significant vascular abnormalities associated with PKD, but the mechanisms underlying this phenomenon remain elusive. Here, we seek to define the molecular events regulating the angiogenic imbalance observed in PKD. Using micro computed tomography (n=7) and protein expression analysis (n=5), we assessed the vascular density and the angiogenic profile of noncystic organs in a well-established PKD rat model (Polycystic Kidney-PCK rat). Heart and lungs of PCK rats have reduced vascular density and decreased expression of angiogenic factors compared with wild type. Similarly, PCK-vascular smooth muscle cells (VSMCs; n=4) exhibited lower levels of vascular markers. Then, using small interfering RNA (n=4), we determined the role of the ciliary protein fibrocystin in wild type-VSMCs, a critical component/regulator of vascular structure and function. Reduction of fibrocystin in wild type-VSMCs (n=4) led to an abnormal angiogenic potential similar to that observed in PCK-VSMCs. Furthermore, we investigated the involvement of the hedgehog signaling, a pathway closely linked to the primary cilium and associated with vascular development, in PKD. Mechanistically, we demonstrated that impairment of the hedgehog signaling mediates, in part, this abnormal angiogenic phenotype. Lastly, overexpression of Gli1 in PCK-VSMCs (n=4) restored the expression levels of proangiogenic molecules. Our data support a critical role of fibrocystin in the abnormal vascular phenotype of PKD and indicate that a dysregulation of hedgehog may be responsible, at least in part, for these vascular deficiencies.
Collapse
Affiliation(s)
- Federico Franchi
- From the Department of Cardiovascular Medicine (F.F., K.M.P., K.Q., D.D., M.O., M.P., M.G.R.-P.), Mayo Clinic, Rochester, MN
| | - Karen M Peterson
- From the Department of Cardiovascular Medicine (F.F., K.M.P., K.Q., D.D., M.O., M.P., M.G.R.-P.), Mayo Clinic, Rochester, MN
| | - Katherine Quandt
- From the Department of Cardiovascular Medicine (F.F., K.M.P., K.Q., D.D., M.O., M.P., M.G.R.-P.), Mayo Clinic, Rochester, MN
| | - David Domnick
- From the Department of Cardiovascular Medicine (F.F., K.M.P., K.Q., D.D., M.O., M.P., M.G.R.-P.), Mayo Clinic, Rochester, MN
| | - Timothy L Kline
- Department of Radiology (T.L.K.), Mayo Clinic, Rochester, MN
| | - Michaela Olthoff
- From the Department of Cardiovascular Medicine (F.F., K.M.P., K.Q., D.D., M.O., M.P., M.G.R.-P.), Mayo Clinic, Rochester, MN
| | - Mojtaba Parvizi
- From the Department of Cardiovascular Medicine (F.F., K.M.P., K.Q., D.D., M.O., M.P., M.G.R.-P.), Mayo Clinic, Rochester, MN
| | - Ezequiel J Tolosa
- Schulze Center for Novel Therapeutic, Division of Oncology Research (E.J.T., M.E.F.-Z.), Mayo Clinic, Rochester, MN
| | - Vicente E Torres
- Division of Nephrology and Hypertension (V.E.T., P.C.H.), Mayo Clinic, Rochester, MN
| | - Peter C Harris
- Division of Nephrology and Hypertension (V.E.T., P.C.H.), Mayo Clinic, Rochester, MN
| | - Martin E Fernandez-Zapico
- Schulze Center for Novel Therapeutic, Division of Oncology Research (E.J.T., M.E.F.-Z.), Mayo Clinic, Rochester, MN
| | - Martin G Rodriguez-Porcel
- From the Department of Cardiovascular Medicine (F.F., K.M.P., K.Q., D.D., M.O., M.P., M.G.R.-P.), Mayo Clinic, Rochester, MN
| |
Collapse
|
6
|
Abstract
Congenital and hereditary cystic lesions of the abdomen are relatively rare. Correct diagnosis is critical as they may simulate several other benign and malignant acquired diseases of the abdomen. With the correct and appropriate use of imaging, diagnosis may be relatively straightforward and clinical management may be implemented appropriately. The purpose of this article is to describe imaging findings of common and uncommon congenital and hereditary cystic disease of the abdominal organs.
Collapse
|
7
|
Wicher D, Grenda R, Teisseyre M, Szymczak M, Halat-Wolska P, Jurkiewicz D, Liebau MC, Ciara E, Rydzanicz M, Kosińska J, Chrzanowska K, Jankowska I. Occurrence of Portal Hypertension and Its Clinical Course in Patients With Molecularly Confirmed Autosomal Recessive Polycystic Kidney Disease (ARPKD). Front Pediatr 2020; 8:591379. [PMID: 33282801 PMCID: PMC7690924 DOI: 10.3389/fped.2020.591379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/04/2020] [Accepted: 09/30/2020] [Indexed: 11/17/2022] Open
Abstract
Purpose: Liver involvement in autosomal recessive polycystic kidney disease (ARPKD) leads to the development of portal hypertension and its complications. The aim of this study was to analyze the occurrence of the portal hypertension and its clinical course and the dynamics in patients with molecularly confirmed ARPKD in a large Polish center. Moreover, the available options in diagnostics, prevention and management of portal hypertension in ARPKD will be discussed. Materials and Methods: The study group consisted of 17 patients aged 2.5-42 years. All patients had ARPKD diagnosis confirmed by molecular tests. Retrospective analysis included laboratory tests, ultrasound and endoscopic examinations, transient elastography and clinical evaluation. Results: Any symptom of portal hypertension was established in 71% of patients. Hypersplenism, splenomegaly, decreased portal flow and esophageal varices were found in 47, 59, 56, and 92% of patients, respectively. Gastrointestinal bleeding occurred in four of 17 patients. Endoscopic variceal ligation (EVL) was performed at least once in nine patients with esophageal varices. Conclusions: Portal hypertension and its complications are present in a significant percentage of ARPKD patients. They should be under the care of multidisciplinary nephrology-gastroenterology/hepatology team. Complications of portal hypertension may occur early in life. Endoscopic methods of preventing gastroesophageal bleeding, such as endoscopic variceal ligation, are effective and surgical techniques, including liver transplantation, are required rarely.
Collapse
Affiliation(s)
- Dorota Wicher
- Department of Medical Genetics, The Children's Memorial Health Institute, Warsaw, Poland
| | - Ryszard Grenda
- Department of Nephrology, Kidney Transplantation and Arterial Hypertension, The Children's Memorial Health Institute, Warsaw, Poland
| | - Mikołaj Teisseyre
- Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The Children's Memorial Health Institute, Warsaw, Poland
| | - Marek Szymczak
- Department of Pediatric Surgery and Organ Transplantation, The Children's Memorial Health Institute, Warsaw, Poland
| | - Paulina Halat-Wolska
- Department of Medical Genetics, The Children's Memorial Health Institute, Warsaw, Poland
| | - Dorota Jurkiewicz
- Department of Medical Genetics, The Children's Memorial Health Institute, Warsaw, Poland
| | - Max Christoph Liebau
- Department of Pediatrics and Center for Molecular Medicine Cologne, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Elżbieta Ciara
- Department of Medical Genetics, The Children's Memorial Health Institute, Warsaw, Poland
| | - Małgorzata Rydzanicz
- Department of Medical Genetics, Center for Biostructure Research First Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland
| | - Joanna Kosińska
- Department of Medical Genetics, Center for Biostructure Research First Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland
| | - Krystyna Chrzanowska
- Department of Medical Genetics, The Children's Memorial Health Institute, Warsaw, Poland
| | - Irena Jankowska
- Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The Children's Memorial Health Institute, Warsaw, Poland
| |
Collapse
|
8
|
Zahid R, Akram M, Rafique E. Prevalence, risk factors and disease knowledge of polycystic kidney disease in Pakistan. Int J Immunopathol Pharmacol 2020; 34:2058738420966083. [PMID: 33125856 PMCID: PMC7607775 DOI: 10.1177/2058738420966083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2019] [Accepted: 09/22/2020] [Indexed: 11/21/2022] Open
Abstract
Polycystic kidneys disease refers to cyst(s) formation in kidneys with severe consequences of end stage renal disease thus have higher mortality. It is a common genetic disease occurring either as autosomal dominant polycystic kidney (ADPKD) or autosomal recessive polycystic kidney disease (ARPKD) with prevalence rates of 1/1000 and 1/40,000 respectively. Dominant forms presenting in later (>30) while recessive in earlier ages (infancy) and affecting both sexes and almost all race. The patient experiences many renal as well as extra-renal manifestations with marked hypertension and cyst formation in other organs predominantly in liver. Due to genetic basis, positive family history is considered as major risk factor. Ultrasonography remains the main stay of diagnosis along with family history, by indicating increased renal size and architectural modifications. Initially disease remains asymptomatic, later on symptomatic treatment is suggested with surgical interventions like cyst decortications or drainage. Dialysis proved to be beneficial in end stage renal disease. However renal transplantation is the treatment of choice.
Collapse
Affiliation(s)
- Rabia Zahid
- Department of Eastern Medicine and Surgery, Government College University Faisalabad, Faisalabad, Pakistan
| | - Muhammad Akram
- Department of Eastern Medicine and Surgery, Government College University Faisalabad, Faisalabad, Pakistan
| | - Ejaz Rafique
- Department of Microbiology, University of Lahore, Lahore, Pakistan
| |
Collapse
|
9
|
Grochowsky A, Gunay-Aygun M. Clinical characteristics of individual organ system disease in non-motile ciliopathies. TRANSLATIONAL SCIENCE OF RARE DISEASES 2019; 4:1-23. [PMID: 31763176 PMCID: PMC6864414 DOI: 10.3233/trd-190033] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Non-motile ciliopathies (disorders of the primary cilia) include autosomal dominant and recessive polycystic kidney diseases, nephronophthisis, as well as multisystem disorders Joubert, Bardet-Biedl, Alström, Meckel-Gruber, oral-facial-digital syndromes, and Jeune chondrodysplasia and other skeletal ciliopathies. Chronic progressive disease of the kidneys, liver, and retina are common features in non-motile ciliopathies. Some ciliopathies also manifest neurological, skeletal, olfactory and auditory defects. Obesity and type 2 diabetes mellitus are characteristic features of Bardet-Biedl and Alström syndromes. Overlapping clinical features and molecular heterogeneity of these ciliopathies render their diagnoses challenging. In this review, we describe the clinical characteristics of individual organ disease for each ciliopathy and provide natural history data on kidney, liver, retinal disease progression and central nervous system function.
Collapse
Affiliation(s)
- Angela Grochowsky
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - Meral Gunay-Aygun
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
- Department of Pediatrics and The McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| |
Collapse
|
10
|
Ultrasound Elastography to Quantify Liver Disease Severity in Autosomal Recessive Polycystic Kidney Disease. J Pediatr 2019; 209:107-115.e5. [PMID: 30902421 PMCID: PMC6535353 DOI: 10.1016/j.jpeds.2019.01.055] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/16/2018] [Revised: 01/09/2019] [Accepted: 01/30/2019] [Indexed: 12/13/2022]
Abstract
OBJECTIVES To evaluate the diagnostic accuracy of ultrasound elastography with acoustic radiation force impulse (ARFI) to detect congenital hepatic fibrosis and portal hypertension in children with autosomal recessive polycystic kidney disease (ARPKD). STUDY DESIGN Cross-sectional study of 25 children with ARPKD and 24 healthy controls. Ultrasound ARFI elastography (Acuson S3000, Siemens Medical Solutions USA, Inc, Malvern, Pennsylvania) was performed to measure shear wave speed (SWS) in the right and left liver lobes and the spleen. Liver and spleen SWS were compared in controls vs ARPKD, and ARPKD without vs with portal hypertension. Linear correlations between liver and spleen SWS, spleen length, and platelet counts were analyzed. Receiver operating characteristic analysis was used to evaluate diagnostic accuracy of ultrasound ARFI elastography. RESULTS Participants with ARPKD had significantly higher median liver and spleen SWS than controls. At a proposed SWS cut-off value of 1.56 m/s, the left liver lobe had the highest sensitivity (92%) and specificity (96%) for distinguishing participants with ARPKD from controls (receiver operating characteristic area 0.92; 95% CI 0.82-1.00). Participants with ARPKD with portal hypertension (splenomegaly and low platelet counts) had significantly higher median liver and spleen stiffness than those without portal hypertension. The left liver lobe also had the highest sensitivity and specificity for distinguishing subjects with ARPKD with portal hypertension. CONCLUSIONS Ultrasound ARFI elastography of the liver and spleen, particularly of the left liver lobe, is a useful noninvasive biomarker to detect and quantify liver fibrosis and portal hypertension in children with ARPKD.
Collapse
|
11
|
Hamo S, Bacchetta J, Bertholet-Thomas A, Ranchin B, Cochat P, Michel-Calemard L. [PKHD1 mutations in autosomal recessive polycystic kidney disease (ARPKD): Genotype-phenotype correlations from a series of 308 cases to improve prenatal counselling]. Nephrol Ther 2018; 14:474-477. [PMID: 29703621 DOI: 10.1016/j.nephro.2018.03.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2017] [Revised: 03/17/2018] [Accepted: 03/18/2018] [Indexed: 12/12/2022]
Abstract
OBJECTIVES ARPKD is a recessive rare disease due to PKHD1 mutation. The main objective of the study was to characterize the phenotypic variability according to the different types of PKHD1 mutations. METHODS This study was performed in 308 ARPKD patients with a genetic diagnosis from our genetic center. Related physicians provided minimal clinical and biological data. RESULTS Patients were divided into three genotypic groups: the first group (G1; n=65) consisted of patients with two truncating mutations, the second group (G2; n=117) of patients with one truncating and one non-truncating mutation, and the third group (G3; n=126) of patients with two non-truncating mutations. In the entire cohort, the outcomes consisted of 31% of pregnancy termination, 18% of neonatal deaths and 51% of patient survival after the neonatal period. The proportion of severe ARPKD (pregnancy termination or neonatal death) was significantly greater in G1: 94% versus 47% in G2 and 27% in G3 (P<0.001). CONCLUSION The presence of two truncating mutations in PKHD1 is associated with the most severe perinatal phenotype. However, the phenotypic variability observed in the other genotypic groups requires caution for prenatal counseling.
Collapse
Affiliation(s)
- Suzy Hamo
- Centre de référence des maladies rénales rares néphrogones, filière ORKID, hôpital Femme-Mère-Enfant, 59, boulevard Pinel, 69677 Bron cedex, France.
| | - Justine Bacchetta
- Centre de référence des maladies rénales rares néphrogones, filière ORKID, hôpital Femme-Mère-Enfant, 59, boulevard Pinel, 69677 Bron cedex, France; Faculté de médecine Lyon Est, université Claude-Bernard Lyon 1, 69008 Lyon, France
| | - Aurélia Bertholet-Thomas
- Centre de référence des maladies rénales rares néphrogones, filière ORKID, hôpital Femme-Mère-Enfant, 59, boulevard Pinel, 69677 Bron cedex, France
| | - Bruno Ranchin
- Centre de référence des maladies rénales rares néphrogones, filière ORKID, hôpital Femme-Mère-Enfant, 59, boulevard Pinel, 69677 Bron cedex, France
| | - Pierre Cochat
- Centre de référence des maladies rénales rares néphrogones, filière ORKID, hôpital Femme-Mère-Enfant, 59, boulevard Pinel, 69677 Bron cedex, France; Faculté de médecine Lyon Est, université Claude-Bernard Lyon 1, 69008 Lyon, France
| | - Laurence Michel-Calemard
- UM pathologies endocriniennes, rénales, musculaires et mucoviscidose, CBPE, groupement hospitalier Est, 59, boulevard Pinel, 69677 Bron cedex, France
| |
Collapse
|
12
|
Willey CJ, Blais JD, Hall AK, Krasa HB, Makin AJ, Czerwiec FS. Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol Dial Transplant 2018; 32:1356-1363. [PMID: 27325254 PMCID: PMC5837385 DOI: 10.1093/ndt/gfw240] [Citation(s) in RCA: 105] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2015] [Accepted: 05/12/2016] [Indexed: 11/14/2022] Open
Abstract
Background Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end-stage renal disease, but estimates of its prevalence vary by >10-fold. The objective of this study was to examine the public health impact of ADPKD in the European Union (EU) by estimating minimum prevalence (point prevalence of known cases) and screening prevalence (minimum prevalence plus cases expected after population-based screening). Methods A review of the epidemiology literature from January 1980 to February 2015 identified population-based studies that met criteria for methodological quality. These examined large German and British populations, providing direct estimates of minimum prevalence and screening prevalence. In a second approach, patients from the 2012 European Renal Association‒European Dialysis and Transplant Association (ERA-EDTA) Registry and literature-based inflation factors that adjust for disease severity and screening yield were used to estimate prevalence across 19 EU countries (N = 407 million). Results Population-based studies yielded minimum prevalences of 2.41 and 3.89/10 000, respectively, and corresponding estimates of screening prevalences of 3.3 and 4.6/10 000. A close correspondence existed between estimates in countries where both direct and registry-derived methods were compared, which supports the validity of the registry-based approach. Using the registry-derived method, the minimum prevalence was 3.29/10 000 (95% confidence interval 3.27-3.30), and if ADPKD screening was implemented in all countries, the expected prevalence was 3.96/10 000 (3.94-3.98). Conclusions ERA-EDTA-based prevalence estimates and application of a uniform definition of prevalence to population-based studies consistently indicate that the ADPKD point prevalence is <5/10 000, the threshold for rare disease in the EU.
Collapse
Affiliation(s)
- Cynthia J Willey
- College of Pharmacy, University of Rhode Island, Kingston, RI, USA
| | - Jaime D Blais
- Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA
| | | | - Holly B Krasa
- Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA
| | - Andrew J Makin
- Otsuka Europe Development and Commercialisation Ltd, Wexham, UK
| | - Frank S Czerwiec
- Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA
| |
Collapse
|
13
|
Wicher D, Jankowska I, Lipiński P, Szymańska-Rożek P, Kmiotek J, Jańczyk W, Rubik J, Chrzanowska K, Socha P. Transient Elastography for Detection of Liver Fibrosis in Children With Autosomal Recessive Polycystic Kidney Disease. Front Pediatr 2018; 6:422. [PMID: 30687687 PMCID: PMC6336693 DOI: 10.3389/fped.2018.00422] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/03/2018] [Accepted: 12/19/2018] [Indexed: 12/19/2022] Open
Abstract
Introduction: Congenital hepatic fibrosis (CHF) is invariably present in all patients with autosomal recessive polycystic kidney disease (ARPKD) but is usually clinically asymptomatic. The portal hypertension in the course of CHF develops and progresses over time, so an early detection of liver fibrosis remains crucial. Aim: The aim of the study was to evaluate a predictive value of transient elastography for evaluating liver disease progress in pediatric ARPKD patients. Material and Methods: The study group encompassed 21 pediatric patients with ARPKD and 20 healthy children (control group) from The Children's Memorial Health Institute in Warsaw, Poland. Liver fibrosis was determined by assessing the liver stiffness (LS) with transient elastography (FibroScan®, FS) using size-appropriate probes. In ARPKD group the laboratory findings, results of an abdominal ultrasound examination, and an endoscopic gastroduodenoscopy were also analyzed. Results: Compared with healthy controls, patients with ARPKD had significantly increased median LS values (22 vs. 4.25 kPa, p < 0.0001). Based on FS results, ARPKD group was divided into two subgroups: patients (n = 5) with LS results suggestive of no fibrosis or minimal fibrosis (LS < 6.9 kPa, METAVIR fibrosis stage 0-1) and patients (n = 16) with LS results suggestive of at least significant liver fibrosis (LS ≥ 6.9 kPa, METAVIR fibrosis stage 2-4). In the first subgroup (no fibrosis or minimal fibrosis), all patients had no signs of portal hypertension. In the subgroup with at least significant liver fibrosis, splenomegaly was observed in 87.5% of patients and thrombocytopenia in 69% of patients. An endoscopic gastroduodenoscopy was performed in 15 out of 21 ARPKD patients, nine patients (60%) had esophageal varices. All of these patients had LS results suggestive of at least significant liver fibrosis. Conclusions: TE by FibroScan can be used as an additional method for evaluating liver disease progress in pediatric ARPKD patients.
Collapse
Affiliation(s)
- Dorota Wicher
- Department of Medical Genetics, The Children's Memorial Health Institute, Warsaw, Poland
| | - Irena Jankowska
- Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, Children's Memorial Health Institute, Warsaw, Poland
| | - Patryk Lipiński
- Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, Children's Memorial Health Institute, Warsaw, Poland
| | | | - Jakub Kmiotek
- Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, Children's Memorial Health Institute, Warsaw, Poland
| | - Wojciech Jańczyk
- Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, Children's Memorial Health Institute, Warsaw, Poland
| | - Jacek Rubik
- Department of Nephrology, Kidney Transplantation and Arterial Hypertension, Children's Memorial Health Institute, Warsaw, Poland
| | - Krystyna Chrzanowska
- Department of Medical Genetics, The Children's Memorial Health Institute, Warsaw, Poland
| | - Piotr Socha
- Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, Children's Memorial Health Institute, Warsaw, Poland
| |
Collapse
|
14
|
Dillman JR, Trout AT, Smith EA, Towbin AJ. Hereditary Renal Cystic Disorders: Imaging of the Kidneys and Beyond. Radiographics 2017; 37:924-946. [PMID: 28493804 DOI: 10.1148/rg.2017160148] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
The purpose of this article is to review the hereditary renal cystic diseases that can manifest in children and adults, with specific attention to pathogenesis and imaging features. Various common and uncommon hereditary renal cystic diseases are reviewed in terms of their underlying etiology, including the involved genetic mutations and the affected proteins and cellular structures. Focus is placed on the morphologic findings in each condition and the features that distinguish one disorder from another. The two most common categories of hereditary renal cystic disease are (a) the ciliopathic disorders, which are related to mutations affecting the primary cilia (called "ciliopathies"), and (b) the phakomatoses. Autosomal dominant polycystic kidney disease, autosomal recessive polycystic kidney disease, and the "medullary cystic disease complex" are all ciliopathies but have different phenotypes. Tuberous sclerosis complex and the associated "contiguous gene syndrome," as well as von Hippel-Lindau syndrome, are phakomatoses that can manifest with cystic renal lesions but have uniquely different extrarenal manifestations. Finally, DICER1 mutations can manifest with renal cystic lesions (typically, cystic nephromas) in patients predisposed to other malignancies in the chest, ovaries, and thyroid. Although some overlap exists in the appearance of the renal cysts associated with each of these diseases, there are clear morphologic differences (eg, cyst size, location, and complexity) that are emphasized in this review. To improve patient outcomes, it is important for the radiologist to recognize the various hereditary renal cystic diseases so that a correct diagnosis is assigned and so that the patient is adequately evaluated and followed up. ©RSNA, 2017.
Collapse
Affiliation(s)
- Jonathan R Dillman
- From the Department of Radiology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229-3039 (J.R.D., A.T.T., A.J.T.); and the Section of Pediatric Radiology, Department of Radiology, University of Michigan Health System, Ann Arbor, Mich (E.A.S.)
| | - Andrew T Trout
- From the Department of Radiology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229-3039 (J.R.D., A.T.T., A.J.T.); and the Section of Pediatric Radiology, Department of Radiology, University of Michigan Health System, Ann Arbor, Mich (E.A.S.)
| | - Ethan A Smith
- From the Department of Radiology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229-3039 (J.R.D., A.T.T., A.J.T.); and the Section of Pediatric Radiology, Department of Radiology, University of Michigan Health System, Ann Arbor, Mich (E.A.S.)
| | - Alexander J Towbin
- From the Department of Radiology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229-3039 (J.R.D., A.T.T., A.J.T.); and the Section of Pediatric Radiology, Department of Radiology, University of Michigan Health System, Ann Arbor, Mich (E.A.S.)
| |
Collapse
|
15
|
Wehrman A, Kriegermeier A, Wen J. Diagnosis and Management of Hepatobiliary Complications in Autosomal Recessive Polycystic Kidney Disease. Front Pediatr 2017; 5:124. [PMID: 28611971 PMCID: PMC5446979 DOI: 10.3389/fped.2017.00124] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/27/2016] [Accepted: 05/08/2017] [Indexed: 12/11/2022] Open
Abstract
Autosomal recessive polycystic kidney disease (ARPKD) is a congenital hepatorenal fibrocystic disease. The hepatic manifestations of ARPKD can range from asymptomatic to portal hypertension and massively dilated biliary system that results in liver transplantation. Hepatic complications of ARPKD typically present with signs of portal hypertension (splenomegaly and thrombocytopenia) or cholangitis. Liver disease in ARPKD does not always correlate with severity of renal disease. Management of ARPKD-related liver disease is largely treating specific symptoms, such as antibiotics for cholangitis or endoscopic treatment for variceal bleeding. If complications cannot be managed medically, liver transplantation may be indicated. This mini-review will discuss the clinical manifestations and management of children with ARPKD liver disease.
Collapse
Affiliation(s)
- Andrew Wehrman
- The Children’s Hospital of Philadelphia, Philadelphia, PA, United States
| | | | - Jessica Wen
- The Children’s Hospital of Philadelphia, Philadelphia, PA, United States
| |
Collapse
|
16
|
Dell KM, Matheson M, Hartung EA, Warady BA, Furth SL. Kidney Disease Progression in Autosomal Recessive Polycystic Kidney Disease. J Pediatr 2016; 171:196-201.e1. [PMID: 26831744 PMCID: PMC5349855 DOI: 10.1016/j.jpeds.2015.12.079] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/18/2015] [Revised: 11/23/2015] [Accepted: 12/30/2015] [Indexed: 11/21/2022]
Abstract
OBJECTIVE To define glomerular filtration rate (GFR) decline, hypertension (HTN), and proteinuria in subjects with autosomal recessive polycystic kidney disease (ARPKD) and compare with 2 congenital kidney disease control groups in the Chronic Kidney Disease in Children cohort. STUDY DESIGN GFR decline (iohexol clearance), rates of HTN (ambulatory/casual blood pressures), antihypertensive medication usage, left ventricular hypertrophy, and proteinuria were analyzed in subjects with ARPKD (n = 22) and 2 control groups: aplastic/hypoplastic/dysplastic disorders (n = 44) and obstructive uropathies (n = 44). Differences between study groups were examined with the Wilcoxon rank sum test. RESULTS Annualized GFR change in subjects with ARPKD was -1.4 mL/min/1.73 m(2) (-6%), with greater decline in subjects age ≥ 10 years (-11.5%). However, overall rates of GFR decline did not differ significantly in subjects with ARPKD vs controls. There were no significant differences in rates of HTN or left ventricular hypertrophy, but subjects with ARPKD had a greater percent on ≥ 3 blood pressure medications (32% vs 0%, P < .0001), more angiotensin-converting enzyme inhibitor use (82% vs 27% vs 36%, P < .0005), and less proteinuria (urine protein: creatinine = 0.1 vs 0.6, P < .005). CONCLUSIONS This study reports rates of GFR decline, HTN, and proteinuria in a small but well-phenotyped ARPKD cohort. The relatively slow rate of GFR decline in subjects with ARPKD and absence of significant proteinuria suggest that these standard clinical measures may have limited utility in assessing therapeutic interventions and highlight the need for other ARPKD kidney disease progression biomarkers.
Collapse
Affiliation(s)
- Katherine M Dell
- Center for Pediatric Nephrology, Cleveland Clinic Children's, Department of Pediatrics, Case Western Reserve University, Cleveland, OH.
| | - Matthew Matheson
- Department of Epidemiology, Johns Hopkins University, Baltimore, MD
| | - Erum A Hartung
- Division of Nephrology, Children's Hospital of Philadelphia, Philadelphia, PA
| | - Bradley A Warady
- Division of Pediatric Nephrology, Children's Mercy Hospital, Kansas City, MO
| | - Susan L Furth
- Division of Nephrology, Children's Hospital of Philadelphia, Philadelphia, PA
| |
Collapse
|
17
|
Chung EM, Conran RM, Schroeder JW, Rohena-Quinquilla IR, Rooks VJ. From the radiologic pathology archives: pediatric polycystic kidney disease and other ciliopathies: radiologic-pathologic correlation. Radiographics 2015; 34:155-78. [PMID: 24428289 DOI: 10.1148/rg.341135179] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Genetic defects of cilia cause a wide range of diseases, collectively known as ciliopathies. Primary, or nonmotile, cilia function as sensory organelles involved in the regulation of cell growth, differentiation, and homeostasis. Cilia are present in nearly every cell in the body and mutations of genes encoding ciliary proteins affect multiple organs, including the kidneys, liver, pancreas, retina, central nervous system (CNS), and skeletal system. Genetic mutations causing ciliary dysfunction result in a large number of heterogeneous phenotypes that can manifest with a variety of overlapping abnormalities in multiple organ systems. Renal manifestations of ciliopathies are the most common abnormalities and include collecting duct dilatation and cyst formation in autosomal recessive polycystic kidney disease (ARPKD), cyst formation anywhere in the nephron in autosomal dominant polycystic kidney disease (ADPKD), and tubulointerstitial fibrosis in nephronophthisis, as well as in several CNS and skeletal malformation syndromes. Hepatic disease is another common manifestation of ciliopathies, ranging from duct dilatation and cyst formation in ARPKD and ADPKD to periportal fibrosis in ARPKD and several malformation syndromes. The unifying molecular pathogenesis of this emerging class of disorders explains the overlap of abnormalities in disparate organ systems and links diseases of widely varied clinical features. It is important for radiologists to be able to recognize the multisystem manifestations of these syndromes, as imaging plays an important role in diagnosis and follow-up of affected patients.
Collapse
Affiliation(s)
- Ellen M Chung
- From the Department of Radiology and Radiological Sciences (E.M.C.) and Department of Pathology (R.M.C.), F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd, Bethesda, MD 20814; Pediatric Radiology Section, American Institute for Radiologic Pathology, Silver Spring, Md (E.M.C.); Department of Radiology, Walter Reed National Military Medical Center, Bethesda, Md (J.W.S., I.R.R.Q.); and Department of Radiology, Tripler Army Medical Center, Honolulu, Hawaii (V.J.R.)
| | | | | | | | | |
Collapse
|
18
|
Büscher R, Büscher AK, Weber S, Mohr J, Hegen B, Vester U, Hoyer PF. Clinical manifestations of autosomal recessive polycystic kidney disease (ARPKD): kidney-related and non-kidney-related phenotypes. Pediatr Nephrol 2014; 29:1915-25. [PMID: 24114580 DOI: 10.1007/s00467-013-2634-1] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/26/2013] [Revised: 09/05/2013] [Accepted: 09/06/2013] [Indexed: 02/23/2023]
Abstract
Autosomal recessive polycystic kidney disease (ARPKD), although less frequent than the dominant form, is a common, inherited ciliopathy of childhood that is caused by mutations in the PKHD1-gene on chromosome 6. The characteristic dilatation of the renal collecting ducts starts in utero and can present at any stage from infancy to adulthood. Renal insufficiency may already begin in utero and may lead to early abortion or oligohydramnios and lung hypoplasia in the newborn. However, there are also affected children who have no evidence of renal dysfunction in utero and who are born with normal renal function. Up to 30 % of patients die in the perinatal period, and those surviving the neonatal period reach end stage renal disease (ESRD) in infancy, early childhood or adolescence. In contrast, some affected patients have been diagnosed as adults with renal function ranging from normal to moderate renal insufficiency to ESRD. The clinical spectrum of ARPKD is broader than previously recognized. While bilateral renal enlargement with microcystic dilatation is the predominant clinical feature, arterial hypertension, intrahepatic biliary dysgenesis remain important manifestations that affect approximately 45 % of infants. All patients with ARPKD develop clinical findings of congenital hepatic fibrosis (CHF); however, non-obstructive dilation of the intrahepatic bile ducts in the liver (Caroli's disease) is seen at the histological level in only a subset of patients. Cholangitis and variceal bleeding, sequelae of portal hypertension, are life-threatening complications that may occur more often in advanced cases of liver disease. In this review we focus on common and uncommon kidney-related and non-kidney-related phenotypes. Clinical management of ARPKD patients should include consideration of potential problems related to these manifestations.
Collapse
Affiliation(s)
- Rainer Büscher
- Children's Hospital, Pediatrics II, University of Duisburg-Essen, Hufelandstr. 55, 45122, Essen, Germany,
| | | | | | | | | | | | | |
Collapse
|
19
|
Hartung EA, Matheson M, Lande MB, Dell KM, Guay-Woodford LM, Gerson AC, Warad BA, Hooper SR, Furth SL. Neurocognition in children with autosomal recessive polycystic kidney disease in the CKiD cohort study. Pediatr Nephrol 2014; 29:1957-65. [PMID: 24828609 PMCID: PMC4167962 DOI: 10.1007/s00467-014-2816-5] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/10/2013] [Revised: 03/18/2014] [Accepted: 03/24/2014] [Indexed: 01/28/2023]
Abstract
BACKGROUND Autosomal recessive polycystic kidney disease (ARPKD) is an inherited disorder characterized by enlarged, cystic kidneys with progressive chronic kidney disease (CKD), systemic hypertension, and congenital hepatic fibrosis. Children with ARPKD can have early onset CKD and severe hypertension, both of which are known to have adverse neurocognitive effects. The objectives of this study were (1) to determine whether ARPKD patients have greater neurocognitive deficits compared to that of children with other causes of CKD, and (2) to examine the relative prevalence of hypertension in ARPKD, a known risk factor for neurocognitive dysfunction. METHODS We performed a cross-sectional, control-matched analysis of 22 ARPKD patients with mild-to-moderate CKD in the Chronic Kidney Disease in Children (CKiD) cohort study, compared with a control group of 44 children with other causes of CKD, matched based on glomerular filtration rate, age at study entry, and age at diagnosis. RESULTS Children with ARPKD in this cohort had neurocognitive functioning comparable to children with other causes of CKD in domains of intellectual functioning, academic achievement, attention regulation, executive functioning, and behavior. Blood pressure parameters were similar between the two groups; however, ARPKD patients required a significantly greater number of antihypertensive medications to achieve similar BP levels. CONCLUSIONS ARPKD patients are potentially at risk for neurocognitive dysfunction due to early onset CKD and more severe hypertension. However, this study of children with mild-to-moderate CKD in the CKiD cohort did not demonstrate increased risk in children with ARPKD compared to children with other causes of CKD. Further studies are needed to determine if these findings are applicable to children with more severe manifestations of ARPKD.
Collapse
Affiliation(s)
- Erum A. Hartung
- Department of Pediatrics, Division of Nephrology, Children’s Hospital of Philadelphia, Philadelphia, PA, United States
| | - Matthew Matheson
- Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States
| | - Marc B. Lande
- Department of Pediatrics, Division of Nephrology, University of Rochester Medical Center, Rochester, NY, United States
| | - Katherine M. Dell
- Department of Pediatrics, Case Western Reserve University and Cleveland Clinic Children’s, Cleveland, OH, United States
| | - Lisa M. Guay-Woodford
- Center for Translational Science, Children’s National Health System, Washington, DC, United States
| | - Arlene C. Gerson
- Departments of Pediatrics and Epidemiology, Johns Hopkins University School of Medicine, Baltimore, MD, United States
| | - Bradley A. Warad
- Division of Pediatric Nephrology, Children’s Mercy Hospital, Kansas City, Missouri, United States
| | - Stephen R. Hooper
- Department of Allied Health Sciences and Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, United States
| | - Susan L. Furth
- Department of Pediatrics, Division of Nephrology, Children’s Hospital of Philadelphia, Philadelphia, PA, United States
| |
Collapse
|
20
|
Hartung EA, Guay-Woodford LM. Autosomal recessive polycystic kidney disease: a hepatorenal fibrocystic disorder with pleiotropic effects. Pediatrics 2014; 134:e833-45. [PMID: 25113295 PMCID: PMC4143997 DOI: 10.1542/peds.2013-3646] [Citation(s) in RCA: 83] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 04/07/2014] [Indexed: 12/31/2022] Open
Abstract
Autosomal recessive polycystic kidney disease (ARPKD) is an important cause of chronic kidney disease in children. The care of ARPKD patients has traditionally been the realm of pediatric nephrologists; however, the disease has multisystem effects, and a comprehensive care strategy often requires a multidisciplinary team. Most notably, ARPKD patients have congenital hepatic fibrosis, which can lead to portal hypertension, requiring close follow-up by pediatric gastroenterologists. In severely affected infants, the diagnosis is often first suspected by obstetricians detecting enlarged, echogenic kidneys and oligohydramnios on prenatal ultrasounds. Neonatologists are central to the care of these infants, who may have respiratory compromise due to pulmonary hypoplasia and massively enlarged kidneys. Surgical considerations can include the possibility of nephrectomy to relieve mass effect, placement of dialysis access, and kidney and/or liver transplantation. Families of patients with ARPKD also face decisions regarding genetic testing of affected children, testing of asymptomatic siblings, or consideration of preimplantation genetic diagnosis for future pregnancies. They may therefore interface with genetic counselors, geneticists, and reproductive endocrinologists. Children with ARPKD may also be at risk for neurocognitive dysfunction and may require neuropsychological referral. The care of patients and families affected by ARPKD is therefore a multidisciplinary effort, and the general pediatrician can play a central role in this complex web of care. In this review, we outline the spectrum of clinical manifestations of ARPKD and review genetics of the disease, clinical and genetic diagnosis, perinatal management, management of organ-specific complications, and future directions for disease monitoring and potential therapies.
Collapse
Affiliation(s)
- Erum A Hartung
- Division of Nephrology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; and
| | - Lisa M Guay-Woodford
- Center for Translational Science, Children's National Health System, Washington, District of Columbia
| |
Collapse
|
21
|
Liver disease in autosomal recessive polycystic kidney disease: clinical characteristics and management in relation to renal failure. J Pediatr Gastroenterol Nutr 2014; 59:190-6. [PMID: 24806835 DOI: 10.1097/mpg.0000000000000422] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
OBJECTIVES We correlated liver and kidney manifestations in a national cohort of patients with autosomal recessive polycystic kidney disease (ARPKD). METHODS A total of 27 consecutive patients with ARPKD were included. Hepatobiliary disorders were comparatively evaluated in 2 groups: children in group 1 (n = 10) displayed renal failure as infants and those in group 2 (n = 17) had normal kidney function through the first year of life. RESULTS Median follow-up time was 10.6 (range, 0.4-40) years. Portal hypertension was diagnosed in 13 patients (48%) at the median age 5.0 (1.5-27.9) years. Esophageal varices developed in 8 patients (30%) at age 8.0 (2.1-11.9) years; 4 patients (15%) had variceal bleeding, and hypersplenism/splenomegaly occurred in 52%, similarly in both groups. Biliary tract dilatation was detected at 2.8 years in group 1 and at 7.9 years in group 2, significantly more frequently in group 1 (60% vs 18%, P = 0.039), causing cholangitis in 2 (20%) versus none in group 2 (P = 0.055). A total of 10 patients (37%) underwent cadaveric liver transplantation (LT) at a median age of 6.6 (1.0-20.0) years. In 1 patient LT was performed because of hepatoblastoma. Nine of these were combined liver-kidney transplantations (CLKT). Patients in group 1 required LT earlier (4.1 years vs 18.2 years, P = 0.017) and more frequently (70% vs 18%, P = 0.01). Overall survival beyond neonatal period was 85%. Two patients died because of infectious complications after CLKT, and 1 patient because of recurrent hepatoblastoma. CONCLUSIONS Although correlation of renal and liver manifestations was variable, biliary dilatation was associated with early renal failure. CLKT may be a treatment for patients with ARPKD with marked hepatobiliary complications.
Collapse
|
22
|
Looking at the (w)hole: magnet resonance imaging in polycystic kidney disease. Pediatr Nephrol 2013; 28:1771-83. [PMID: 23239392 DOI: 10.1007/s00467-012-2370-y] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/08/2012] [Revised: 10/23/2012] [Accepted: 10/24/2012] [Indexed: 12/29/2022]
Abstract
Inherited cystic kidney diseases, including autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD), are the most common monogenetic causes of end-stage renal disease (ESRD) in children and adults. While ARPKD is a rare and usually severe pediatric disease, the more common ADPKD typically shows a slowly progressive course leading to ESRD in adulthood. At the present time there is no established disease-modifying treatment for either ARPKD or ADPKD. Various therapeutic approaches are currently under investigation, such as V2 receptor antagonists, somatostatins, and mTOR inhibitors. Renal function remains stable for decades in ADPKD, and thus clinically meaningful surrogate markers to assess therapeutic efficacy are needed. Various studies have pointed out that total kidney volume (TKV) is a potential surrogate parameter for disease severity in ADPKD. Recent trials have therefore measured TKV by magnet resonance imaging (MRI) to monitor and to predict disease progression. Here, we discuss novel insights on polycystic kidney disease (PKD), the value of MRI, and the measurement of TKV in the diagnosis and follow-up of PKD, as well as novel emerging therapeutic strategies for ADPKD.
Collapse
|
23
|
Abstract
BACKGROUND AND OBJECTIVE Congenital hepatic fibrosis (CHF) and Caroli syndrome are frequently associated with renal cystic diseases. They have a variable clinical course, and the natural history is not well defined despite molecular advances. Our study describes the clinical manifestations and long-term outcome in children with this disorder. METHODS A retrospective case review of children with CHF at a single centre diagnosed on the basis of clinical features, radiological and endoscopic evidence of portal hypertension (PHT), and compatible histopathological findings. Children were categorised based on hepatic phenotype-group 1 (Caroli syndrome) and group 2 (CHF). Hepatobiliary as well as renal manifestations were recorded at presentation, and their evolution followed up until transplant or last follow-up. RESULTS There were 40 children (22 boys) with a median age of 1.3 years at clinical presentation. Fourteen of 40 (35%) children presented in the neonatal period with primarily renal disease, of whom 11 (78%) had Caroli syndrome (P = 0.02). Significant PHT with oesophageal varices was seen in 86%, with no difference in the incidence of gastrointestinal bleeding and varices between Caroli syndrome and CHF. Cholangitis developed in 10 of 40 (25%) and was more common in the Caroli syndrome group (P = 0.009). A higher proportion of children with Caroli syndrome developed chronic kidney disease (CKD) stage 3 and above as compared with CHF (85% vs 42%; P = 0.007). Twelve of 21 (57%) and 8 of 19 (42%) children in the Caroli syndrome and CHF groups required either combined liver-kidney or isolated liver transplant, with the most common indication for renal transplantation being end-stage renal disease (CKD5d) with or without advanced PHT or cholangitis. All 14 (100%) children with neonatal presentation developed CKD5d and required combined liver-kidney transplant before 14 years of age, whereas 77% of children presenting beyond the neonatal period survived without liver-kidney transplant (P < 0.001). Neonatal presentation was the best predictor of the need for transplant. CONCLUSIONS Caroli syndrome is more likely to present in the neonatal period and these patients are more likely to develop CKD5d. CKD stage 3 or above with recurrent cholangitis is more common in Caroli syndrome presenting beyond the neonatal period and adds to the significant morbidity in these patients. Children presenting in the neonatal period have a more severe phenotype and should be considered early for combined liver-kidney transplant.
Collapse
|
24
|
Gunay–Aygun M, Font–Montgomery E, Lukose L, Gerstein MT, Piwnica–Worms K, Choyke P, Daryanani KT, Turkbey B, Fischer R, Bernardini I, Sincan M, Zhao X, Sandler NG, Roque A, Douek DC, Graf J, Huizing M, Bryant JC, Mohan P, Gahl WA, Heller T. Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease. Gastroenterology 2013; 144:112-121.e2. [PMID: 23041322 PMCID: PMC4162098 DOI: 10.1053/j.gastro.2012.09.056] [Citation(s) in RCA: 102] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/29/2012] [Revised: 09/22/2012] [Accepted: 09/25/2012] [Indexed: 02/06/2023]
Abstract
BACKGROUND & AIMS Autosomal recessive polycystic kidney disease (ARPKD), the most common ciliopathy of childhood, is characterized by congenital hepatic fibrosis and progressive cystic degeneration of kidneys. We aimed to describe congenital hepatic fibrosis in patients with ARPKD, confirmed by detection of mutations in PKHD1. METHODS Patients with ARPKD and congenital hepatic fibrosis were evaluated at the National Institutes of Health from 2003 to 2009. We analyzed clinical, molecular, and imaging data from 73 patients (age, 1-56 years; average, 12.7 ± 13.1 years) with kidney and liver involvement (based on clinical, imaging, or biopsy analyses) and mutations in PKHD1. RESULTS Initial symptoms were liver related in 26% of patients, and others presented with kidney disease. One patient underwent liver and kidney transplantation, and 10 others received kidney transplants. Four presented with cholangitis and one with variceal bleeding. Sixty-nine percent of patients had enlarged left lobes on magnetic resonance imaging, 92% had increased liver echogenicity on ultrasonography, and 65% had splenomegaly. Splenomegaly started early in life; 60% of children younger than 5 years had enlarged spleens. Spleen volume had an inverse correlation with platelet count and prothrombin time but not with serum albumin level. Platelet count was the best predictor of spleen volume (area under the curve of 0.88905), and spleen length corrected for patient's height correlated inversely with platelet count (R(2) = 0.42, P < .0001). Spleen volume did not correlate with renal function or type of PKHD1 mutation. Twenty-two of 31 patients who underwent endoscopy were found to have varices. Five had variceal bleeding, and 2 had portosystemic shunts. Forty-percent had Caroli syndrome, and 30% had an isolated dilated common bile duct. CONCLUSIONS Platelet count is the best predictor of the severity of portal hypertension, which has early onset but is underdiagnosed in patients with ARPKD. Seventy percent of patients with ARPKD have biliary abnormalities. Kidney and liver disease are independent, and variability in severity is not explainable by type of PKHD1 mutation; ClinicalTrials.gov number, NCT00068224.
Collapse
Affiliation(s)
- Meral Gunay–Aygun
- Medical Genetics Branch, National Human Genome Research Institute, Bethesda, Maryland,The Intramural Program of the Office of Rare Diseases, Bethesda, Maryland
| | | | - Linda Lukose
- Medical Genetics Branch, National Human Genome Research Institute, Bethesda, Maryland
| | - Maya Tuchman Gerstein
- Medical Genetics Branch, National Human Genome Research Institute, Bethesda, Maryland
| | - Katie Piwnica–Worms
- Medical Genetics Branch, National Human Genome Research Institute, Bethesda, Maryland
| | - Peter Choyke
- Molecular Imaging Program, National Cancer Institute, Bethesda, Maryland
| | | | - Baris Turkbey
- Molecular Imaging Program, National Cancer Institute, Bethesda, Maryland
| | - Roxanne Fischer
- Medical Genetics Branch, National Human Genome Research Institute, Bethesda, Maryland
| | - Isa Bernardini
- Medical Genetics Branch, National Human Genome Research Institute, Bethesda, Maryland
| | - Murat Sincan
- Medical Genetics Branch, National Human Genome Research Institute, Bethesda, Maryland
| | - Xiongce Zhao
- Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland
| | - Netanya G. Sandler
- Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
| | - Annelys Roque
- Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
| | - Daniel C. Douek
- Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
| | - Jennifer Graf
- Medical Genetics Branch, National Human Genome Research Institute, Bethesda, Maryland
| | - Marjan Huizing
- Medical Genetics Branch, National Human Genome Research Institute, Bethesda, Maryland
| | - Joy C. Bryant
- Medical Genetics Branch, National Human Genome Research Institute, Bethesda, Maryland
| | - Parvathi Mohan
- Department of Pediatric Gastroenterology, George Washington University, Washington, DC
| | - William A. Gahl
- Medical Genetics Branch, National Human Genome Research Institute, Bethesda, Maryland,The Intramural Program of the Office of Rare Diseases, Bethesda, Maryland
| | - Theo Heller
- Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland
| |
Collapse
|
25
|
Cordiner DS, Evans CA, Brundler MA, McPhillips M, Murio E, Darling M, Taheri S. A complex case of congenital cystic renal disease. BMJ Case Rep 2012; 2012:bcr.12.2011.5463. [PMID: 22605879 DOI: 10.1136/bcr.12.2011.5463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
This case outlines the potential complexity of autosomal recessive polycystic kidney disease (ARPKD). It highlights the challenges involved in managing this condition, some of the complications faced and areas of uncertainty in the decision making process. With a paucity of published paediatric cases on this subject, this should add to the pool of information currently available.
Collapse
Affiliation(s)
- David S Cordiner
- Department of Paediatrics, Royal Hospital for Sick Children, Edinburgh, UK.
| | | | | | | | | | | | | |
Collapse
|
26
|
Malek J, Daar J. The case for a parental duty to use preimplantation genetic diagnosis for medical benefit. THE AMERICAN JOURNAL OF BIOETHICS : AJOB 2012; 12:3-11. [PMID: 22452463 DOI: 10.1080/15265161.2012.656798] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
This article explores the possibility that there is a parental duty to use preimplantation genetic diagnosis (PGD) for the medical benefit of future children. Using one genetic disorder as a paradigmatic example, we find that such a duty can be supported in some situations on both ethical and legal grounds. Our analysis shows that an ethical case in favor of this position can be made when potential parents are aware that a possible future child is at substantial risk of inheriting a serious genetic condition. We further argue that a legal case for a duty to use PGD for medical benefit can be made in situations in which potential parents have chosen to conceive through in vitro fertilization and know that any children conceived are at substantial risk of having a serious genetic condition.
Collapse
Affiliation(s)
- Janet Malek
- Brody School of Medicine, Bioethics and Interdisciplinary Studies, Greenville, NC 27834, USA.
| | | |
Collapse
|
27
|
Halvorson CR, Bremmer MS, Jacobs SC. Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment. Int J Nephrol Renovasc Dis 2010; 3:69-83. [PMID: 21694932 PMCID: PMC3108786 DOI: 10.2147/ijnrd.s6939] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2010] [Indexed: 01/09/2023] Open
Abstract
Both autosomal dominant and recessive polycystic kidney disease are conditions with severe associated morbidity and mortality. Recent advances in the understanding of the genetic and molecular pathogenesis of both ADPKD and ARPKD have resulted in new, targeted therapies designed to disrupt cell signaling pathways responsible for the abnormal cell proliferation, dedifferentiation, apoptosis, and fluid secretion characteristic of the disease. Herein we review the current understanding of the pathophysiology of these conditions, as well as the current treatments derived from our understanding of the mechanisms of these diseases.
Collapse
Affiliation(s)
- Christian R Halvorson
- Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.
| | | | | |
Collapse
|
28
|
Jia G, Kwon M, Liang HL, Mortensen J, Nilakantan V, Sweeney WE, Park F. Chronic treatment with lisinopril decreases proliferative and apoptotic pathways in autosomal recessive polycystic kidney disease. Pediatr Nephrol 2010; 25:1139-46. [PMID: 20229187 DOI: 10.1007/s00467-010-1477-2] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/06/2009] [Revised: 01/19/2010] [Accepted: 01/25/2010] [Indexed: 02/04/2023]
Abstract
Angiotensin converting enzyme (ACE) inhibition is a common therapeutic modality in the treatment of autosomal recessive polycystic kidney disease (ARPKD). This study was designed to investigate whether chronic inhibition of ACE would have a therapeutic effect in attenuating the progression of renal cystogenesis in an orthologous rat model of ARPKD, the polycystic kidney (PCK) rat. Lisinopril (3 mg/kg per day) was administered orally for a period of 12 weeks, beginning at post-natal week 4. Lisinopril treatment resulted in an approximately 30% improvement in the collecting duct cystic indices (CT CI) of PCK animals. Activation of extracellular signal-regulated kinase 1 (ERK1) and 2 (ERK2), proliferative signaling markers, and proliferating cell nuclear antigen (PCNA), an end-point marker for proliferation, was reduced following chronic treatment with lisinopril compared to that in vehicle-treated PCK rats. To assess whether apoptotic pathways were altered due to chronic ACE inhibition, we examined p38 mitogen activated protein kinase (MAPK) and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), which are markers of apoptotic signaling cascades. p38 MAPK was significantly reduced (P < 0.0001) following chronic treatment with lisinopril, but no change in the activation of SAPK/JNK could be detected by immunoblot analysis. Lisinopril treatment resulted in a significant reduction (P < 0.01) in cleaved caspase-7 levels, but not caspase-3 activity, in PCK rat kidneys compared to the vehicle-treated PCK rat kidneys. Proteinuria was completely ameliorated in the presence of chronic ACE inhibition in the lisinopril-treated rats compared with the vehicle-treated PCK rats. In all, these findings demonstrated that chronic ACE inhibition can beneficially alter proliferative and apoptotic pathways to promote therapeutic reductions in renal cyst development in ARPKD.
Collapse
Affiliation(s)
- Guangfu Jia
- Department of Medicine, Division of Nephrology, Medical College of Wisconsin, 8701 Watertown Plank Road, HRC 4100, Milwaukee, WI 53226, USA
| | | | | | | | | | | | | |
Collapse
|
29
|
Gunay-Aygun M, Font-Montgomery E, Lukose L, Tuchman M, Graf J, Bryant JC, Kleta R, Garcia A, Edwards H, Piwnica-Worms K, Adams D, Bernardini I, Fischer RE, Krasnewich D, Oden N, Ling A, Quezado Z, Zak C, Daryanani KT, Turkbey B, Choyke P, Guay-Woodford LM, Gahl WA. Correlation of kidney function, volume and imaging findings, and PKHD1 mutations in 73 patients with autosomal recessive polycystic kidney disease. Clin J Am Soc Nephrol 2010; 5:972-84. [PMID: 20413436 DOI: 10.2215/cjn.07141009] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
BACKGROUND AND OBJECTIVES Renal function and imaging findings have not been comprehensively and prospectively characterized in a broad age range of patients with molecularly confirmed autosomal recessive polycystic kidney disease (ARPKD). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS Ninety potential ARPKD patients were examined at the National Institutes of Health Clinical Center. Seventy-three fulfilled clinical diagnostic criteria, had at least one PKHD1 mutation, and were prospectively evaluated using magnetic resonance imaging (MRI), high-resolution ultrasonography (HR-USG), and measures of glomerular and tubular function. RESULTS Among 31 perinatally symptomatic patients, 25% required renal replacement therapy by age 11 years; among 42 patients who became symptomatic beyond 1 month (nonperinatal), 25% required kidney transplantation by age 32 years. Creatinine clearance (CrCl) for nonperinatal patients (103 +/- 54 ml/min/1.73 m(2)) was greater than for perinatal patients (62 +/- 33) (P = 0.002). Corticomedullary involvement on HR-USG was associated with a significantly worse mean CrCl (61 +/- 32) in comparison with medullary involvement only (131 +/- 46) (P < 0.0001). Among children with enlarged kidneys, volume correlated inversely with function, although with wide variability. Severity of PKHD1 mutations did not determine kidney size or function. In 35% of patients with medullary-only abnormalities, standard ultrasound was normal and the pathology was detectable with HR-USG. CONCLUSIONS In ARPKD, perinatal presentation and corticomedullary involvement are associated with faster progression of kidney disease. Mild ARPKD is best detected by HR-USG. Considerable variability occurs that is not explained by the type of PKHD1 mutation.
Collapse
Affiliation(s)
- Meral Gunay-Aygun
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Harrison JL, Hildreth CM, Callahan SM, Goodchild AK, Phillips JK. Cardiovascular autonomic dysfunction in a novel rodent model of polycystic kidney disease. Auton Neurosci 2010; 152:60-6. [DOI: 10.1016/j.autneu.2009.09.019] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2009] [Revised: 09/14/2009] [Accepted: 09/25/2009] [Indexed: 11/16/2022]
|
31
|
Genotype-phenotype correlations in fetuses and neonates with autosomal recessive polycystic kidney disease. Kidney Int 2009; 77:350-8. [PMID: 19940839 DOI: 10.1038/ki.2009.440] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The prognosis of autosomal recessive polycystic kidney disease is known to correlate with genotype. The presence of two truncating mutations in the PKHD1 gene encoding the fibrocystin protein is associated with neonatal death while patients who survive have at least one missense mutation. To determine relationships between genotype and renal and hepatic abnormalities we correlated the severity of renal and hepatic histological lesions to the type of PKHD1 mutations in 54 fetuses (medical pregnancy termination) and 20 neonates who died shortly after birth. Within this cohort, 55.5% of the mutations truncated fibrocystin. The severity of cortical collecting duct dilatations, cortical tubule and glomerular lesions, and renal cortical and hepatic portal fibrosis increased with gestational age. Severe genotypes, defined by two truncating mutations, were more frequent in patients of less than 30 weeks gestation compared to older fetuses and neonates. When adjusted to gestational age, the extension of collecting duct dilatation into the cortex and cortical tubule lesions, but not portal fibrosis, was more prevalent in patients with severe than in those with a non-severe genotype. Our results show the presence of two truncating mutations of the PKHD1 gene is associated with the most severe renal forms of prenatally detected autosomal recessive polycystic kidney disease. Their absence, however, does not guarantee survival to the neonatal period.
Collapse
|
32
|
Gunay-Aygun M. Liver and kidney disease in ciliopathies. AMERICAN JOURNAL OF MEDICAL GENETICS. PART C, SEMINARS IN MEDICAL GENETICS 2009; 151C:296-306. [PMID: 19876928 PMCID: PMC2919058 DOI: 10.1002/ajmg.c.30225] [Citation(s) in RCA: 145] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Hepatorenal fibrocystic diseases (HRFCDs) are among the most common inherited human disorders. The discovery that proteins defective in the autosomal dominant and recessive polycystic kidney diseases (ADPKD and ARPKD) localize to the primary cilia and the recognition of the role these organelles play in the pathogenesis of HRFCDs led to the term "ciliopathies." While ADPKD and ARPKD are the most common ciliopathies associated with both liver and kidney disease, variable degrees of renal and/or hepatic involvement occur in many other ciliopathies, including Joubert, Bardet-Biedl, Meckel-Gruber, and oral-facial-digital syndromes. The ductal plate malformation (DPM), a developmental abnormality of the portobiliary system, is the basis of the liver disease in ciliopathies that manifest congenital hepatic fibrosis (CHF), Caroli syndrome (CS), and polycystic liver disease (PLD). Hepatocellular function remains relatively preserved in ciliopathy-associated liver diseases. The major morbidity associated with CHF is portal hypertension (PH), often leading to esophageal varices and hypersplenism. In addition, CD predisposes to recurrent cholangitis. PLD is not typically associated with PH, but may result in complications due to mass effects. The kidney pathology in ciliopathies ranges from non-functional cystic dysplastic kidneys to an isolated urinary concentration defect; the disorders contributing to this pathology, in addition to ADPKD and ARPKD, include nephronophithisis (NPHP), glomerulocystic kidney disease and medullary sponge kidneys. Decreased urinary concentration ability, resulting in polyuria and polydypsia, is the first and most common renal symptom in ciliopathies. While the majority of ADPKD, ARPKD, and NPHP patients require renal transplantation, the frequency and rate of progression to renal failure varies considerably in other ciliopathies. This review focuses on the kidney and liver disease found in the different ciliopathies.
Collapse
Affiliation(s)
- Meral Gunay-Aygun
- Section on Human Biochemical Genetics, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, 10 Center Dr., Bldg 10, Rm. 10C103, Bethesda, MD 20892-1851, USA.
| |
Collapse
|
33
|
Gunay-Aygun M, Parisi MA, Doherty D, Tuchman M, Tsilou E, Kleiner DE, Huizing M, Turkbey B, Choyke P, Guay-Woodford L, Heller T, Szymanska K, Johnson CA, Glass I, Gahl WA. MKS3-related ciliopathy with features of autosomal recessive polycystic kidney disease, nephronophthisis, and Joubert Syndrome. J Pediatr 2009; 155:386-92.e1. [PMID: 19540516 PMCID: PMC2925444 DOI: 10.1016/j.jpeds.2009.03.045] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/25/2008] [Revised: 01/20/2009] [Accepted: 03/20/2009] [Indexed: 01/15/2023]
Abstract
OBJECTIVES To describe 3 children with mutations in a Meckel syndrome gene (MKS3), with features of autosomal recessive polycystic kidney disease (ARPKD), nephronophthisis, and Joubert syndrome (JS). STUDY DESIGN Biochemical evaluations, magnetic resonance and ultrasound imaging, electroretinograms, IQ testing, and sequence analysis of the PKHD1 and MKS3 genes were performed. Functional consequences of the MKS3 mutations were evaluated by cDNA sequencing and transfection studies with constructs of meckelin, the protein product of MKS3. RESULTS These 3 children with MKS3 mutations had features typical of ARPKD, that is, enlarged, diffusely microcystic kidneys and early-onset severe hypertension. They also exhibited early-onset chronic anemia, a feature of nephronophthisis, and speech and oculomotor apraxia, suggestive of JS. Magnetic resonance imaging of the brain, originally interpreted as normal, revealed midbrain and cerebellar abnormalities in the spectrum of the "molar tooth sign" that characterizes JS. CONCLUSIONS These findings expand the phenotypes associated with MKS3 mutations. MKS3-related ciliopathies should be considered in patients with an ARPKD-like phenotype, especially in the presence of speech and oculomotor apraxia. In such patients, careful expert evaluation of the brain images can be beneficial because the brain malformations can be subtle.
Collapse
Affiliation(s)
- Meral Gunay-Aygun
- Medical Genetics Branch, National Human Genome Research Institute, Bethesda, MD 20892, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Seeman T, Malíková M, Bláhová K, Seemanová E. Polycystic kidney and hepatic disease with mental retardation and hand anomalies in three siblings. Pediatr Nephrol 2009; 24:1409-12. [PMID: 19011905 DOI: 10.1007/s00467-008-1049-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/10/2008] [Revised: 09/30/2008] [Accepted: 10/21/2008] [Indexed: 01/25/2023]
Abstract
A family with three children affected with congenital polycystic kidneys, hepatic fibrosis, mental retardation, minor anomalies of the hands, and dysmorphic facial features is reported. All children progressed to chronic renal failure. Linkage to the locus for autosomal recessive polycystic kidney disease was excluded by haplotype analysis. The family is endogamic, and the affected siblings are of both sexes, which is in agreement with an autosomal recessive determination of this syndrome. A similar syndrome was reported in 1990 by Labrune et al. [J Pediatr Gastroenterol Nutr (1990) 10:540-543]. Our report provides further evidence for the etiological heterogeneity of polycystic kidney with hepatic fibrosis. The syndrome reported here should be considered in the differential diagnosis of the early manifestation of polycystic kidneys. Mental retardation and hand anomalies are the hallmarks for the differential diagnosis of this syndrome.
Collapse
Affiliation(s)
- Tomás Seeman
- Department of Pediatrics, Second Medical School, University Hospital Motol, Charles University Prague, V Uvalu 84, 15006, Prague, Czech Republic.
| | | | | | | |
Collapse
|
35
|
Kim I, Li C, Liang D, Chen XZ, Coffy RJ, Ma J, Zhao P, Wu G. Polycystin-2 expression is regulated by a PC2-binding domain in the intracellular portion of fibrocystin. J Biol Chem 2008; 283:31559-66. [PMID: 18782757 DOI: 10.1074/jbc.m805452200] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Autosomal dominant (ADPKD) and autosomal recessive (ARPKD) polycystic kidney disease are caused by mutations in Pkd1/Pkd2 and Pkhd1, which encode polycystins (PCs) and fibrocystin/polyductin (FPC). Our recent study reported that a deficiency in FPC increases the severity of cystic disease in Pkd2 mutants and down-regulates PC2 in vivo, but the precise molecular mechanism of these effects is unknown (Kim, I., Fu, Y., Hui, K., Moeckel, G., Mai, W., Li, C., Liang, D., Zhao, P., Ma, J., Chen, X.-Z., George, A. L., Jr., Coffey, R. J., Feng, Z. P., and Wu, G. (2008) J. Am. Soc. Nephrol. 19, 455-468). In this study, through the use of deletion and mutagenesis strategies, we identified a PC2-binding domain in the intracellular C terminus of FPC and an FPC-binding domain in the intracellular N terminus of PC2. These binding domains provide a molecular basis for the physical interaction between PC2 and FPC. In addition, we also found that physical interaction between the binding domains of PC2 and FPC is able to prevent down-regulation of PC2 induced by loss of FPC. In vivo, we generated a mouse model of ADPKD with hypomorphic Pkd2 alleles (Pkd2nf3/nf3) and show that PC2 down-regulation is accompanied by a phenotype similar to that of Pkhd1(-/-) mice. These findings demonstrate a common mechanism underlying cystogenesis in ADPKD and ARPKD and provide insight into the molecular relationship between PC2 and FPC.
Collapse
Affiliation(s)
- Ingyu Kim
- Departmentof Medicine, Vanderbilt University, Nashville, Tennessee 37232, USA
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Arbeiter A, Büscher R, Bonzel KE, Wingen AM, Vester U, Wohlschläger J, Zerres K, Nürnberger J, Bergmann C, Hoyer PF. Nephrectomy in an autosomal recessive polycystic kidney disease (ARPKD) patient with rapid kidney enlargement and increased expression of EGFR. Nephrol Dial Transplant 2008; 23:3026-9. [PMID: 18503009 DOI: 10.1093/ndt/gfn288] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Affiliation(s)
- Anja Arbeiter
- Department of Pediatrics II, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Flores J, Arnon R, Morotti RA, Guay-Woodford L, Emre S, Shneider BL. Rapid evolution of congenital hepatic fibrosis after liver transplantation for acute liver failure: the potential role of extrahepatic factors. Liver Transpl 2008; 14:660-4. [PMID: 18433070 DOI: 10.1002/lt.21415] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
A 9-year-old male underwent deceased donor liver transplantation for idiopathic fulminant hepatic failure. In the postoperative period, a review of perioperative biopsies of the donor liver revealed mild features of congenital hepatic fibrosis. Over the ensuing year, the recipient developed severe complications of congenital hepatic fibrosis including multiple episodes of cholangitis and progressive portal hypertension. After a second transplant, the patient had no further episodes of cholangitis and/or features of portal hypertension. Examination of the explanted liver revealed remarkable progression of the congenital hepatic fibrosis, suggesting that the phenotype of this disease may be dependent in part on extrahepatic factors.
Collapse
Affiliation(s)
- Judith Flores
- Department of Gastroenterology, Hospital de Pediatria, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico
| | | | | | | | | | | |
Collapse
|
38
|
Kim I, Fu Y, Hui K, Moeckel G, Mai W, Li C, Liang D, Zhao P, Ma J, Chen XZ, George AL, Coffey RJ, Feng ZP, Wu G. Fibrocystin/polyductin modulates renal tubular formation by regulating polycystin-2 expression and function. J Am Soc Nephrol 2008; 19:455-68. [PMID: 18235088 DOI: 10.1681/asn.2007070770] [Citation(s) in RCA: 90] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Autosomal recessive polycystic kidney disease is caused by mutations in PKHD1, which encodes the membrane-associated receptor-like protein fibrocystin/polyductin (FPC). FPC associates with the primary cilia of epithelial cells and co-localizes with the Pkd2 gene product polycystin-2 (PC2), suggesting that these two proteins may function in a common molecular pathway. For investigation of this, a mouse model with a gene-targeted mutation in Pkhd1 that recapitulates phenotypic characteristics of human autosomal recessive polycystic kidney disease was produced. The absence of FPC is associated with aberrant ciliogenesis in the kidneys of Pkhd1-deficient mice. It was found that the COOH-terminus of FPC and the NH2-terminus of PC2 interact and that lack of FPC reduced PC2 expression but not vice versa, suggesting that PC2 may function immediately downstream of FPC in vivo. PC2-channel activities were dysregulated in cultured renal epithelial cells derived from Pkhd1 mutant mice, further supporting that both cystoproteins function in a common pathway. In addition, mice with mutations in both Pkhd1 and Pkd2 had a more severe renal cystic phenotype than mice with single mutations, suggesting that FPC acts as a genetic modifier for disease severity in autosomal dominant polycystic kidney disease that results from Pkd2 mutations. It is concluded that a functional and molecular interaction exists between FPC and PC2 in vivo.
Collapse
Affiliation(s)
- Ingyu Kim
- Division of Genetic Medicine, Department of Medicine and Cell and Developmental Biology, Vanderbilt University, 539 LH, 2215 Garland Avenue, Nashville, TN 37232, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Menezes LF, Onuchic LF. Molecular and cellular pathogenesis of autosomal recessive polycystic kidney disease. Braz J Med Biol Res 2007; 39:1537-48. [PMID: 17160262 DOI: 10.1590/s0100-879x2006001200004] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2006] [Accepted: 08/29/2006] [Indexed: 11/22/2022] Open
Abstract
Autosomal recessive polycystic kidney disease (ARPKD) is an inherited disease characterized by a malformation complex which includes cystically dilated tubules in the kidneys and ductal plate malformation in the liver. The disorder is observed primarily in infancy and childhood, being responsible for significant pediatric morbidity and mortality. All typical forms of ARPKD are caused by mutations in a single gene, PKHD1 (polycystic kidney and hepatic disease 1). This gene has a minimum of 86 exons, assembled into multiple differentially spliced transcripts and has its highest level of expression in kidney, pancreas and liver. Mutational analyses revealed that all patients with both mutations associated with truncation of the longest open reading frame-encoded protein displayed the severe phenotype. This product, polyductin, is a 4,074-amino acid protein expressed in the cytoplasm, plasma membrane and primary apical cilia, a structure that has been implicated in the pathogenesis of different polycystic kidney diseases. In fact, cholangiocytes isolated from an ARPKD rat model develop shorter and dysmorphic cilia, suggesting polyductin to be important for normal ciliary morphology. Polyductin seems also to participate in tubule morphogenesis and cell mitotic orientation along the tubular axis. The recent advances in the understanding of in vitro and animal models of polycystic kidney diseases have shed light on the molecular and cellular mechanisms of cyst formation and progression, allowing the initiation of therapeutic strategy designing and promising perspectives for ARPKD patients. It is notable that vasopressin V2 receptor antagonists can inhibit/halt the renal cystic disease progression in an orthologous rat model of human ARPKD.
Collapse
Affiliation(s)
- L F Menezes
- Disciplina de Nefrologia, Departamento de Clínica Médica, Faculdade de Medicina, Universidade de São Paulo, Av. Dr. Arnaldo 455, Sala 3310, 01246-903 São Paulo, SP, Brazil.
| | | |
Collapse
|
40
|
Abstract
A retrospective analysis was conducted on 10 consecutive cases of neonatal ARPKD, 9 of whom received kidney transplants (KT). All were diagnosed antenatally (n = 6) or at birth. In the first month of life 70% required ventilatory support. Pre-emptive bilateral nephrectomy and peritoneal dialysis (PD) catheter placement were performed in 9 at a mean age of 7.8 +/- 11.9 months. The indications for nephrectomy were massive kidneys, resulting in suboptimal nutrition and respiratory compromise. All patients received assisted enteral nutrition, with significant increase in mean tolerated feeds following nephrectomy (p < 0.05), with increase in mean normalized weight and height (0.92 and 1.2 delta SDS respectively), by one year post-transplantation. KT was performed at a mean age and weight of 2.5 +/- 1.4 years and 13.3 +/- 6.1 kg. The mean creatinine clearance at one year post-KT was 91.3 +/- 38.1 mls/min/1.73 m(2), with a projected graft life expectancy of 18.4 years. Patient survival was 89% and death censored graft survival was 100%, at a mean follow-up of 6.1 +/- 4.5 years post-transplant. Six patients demonstrated evidence of hepatic fibrosis, one of which required liver transplantation. In patients with massive kidneys from ARPKD, pre-emptive bilateral nephrectomy, supportive PD and early aggressive nutrition, can minimize early infant mortality, so that subsequent KT can be performed with excellent patient and graft survival.
Collapse
Affiliation(s)
- Mona Beaunoyer
- Department of Transplant Surgery, Stanford University, Stanford, CA 94304, USA
| | | | | | | | | | | |
Collapse
|
41
|
Phillips JK, Hopwood D, Loxley RA, Ghatora K, Coombes JD, Tan YS, Harrison JL, McKitrick DJ, Holobotvskyy V, Arnolda LF, Rangan GK. Temporal relationship between renal cyst development, hypertension and cardiac hypertrophy in a new rat model of autosomal recessive polycystic kidney disease. Kidney Blood Press Res 2007; 30:129-44. [PMID: 17446713 DOI: 10.1159/000101828] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2006] [Accepted: 02/06/2007] [Indexed: 01/03/2023] Open
Abstract
BACKGROUND/METHODS We have examined the hypothesis that cyst formation is key in the pathogenesis of cardiovascular disease in a Lewis polycystic kidney (LPK) model of autosomal-recessive polycystic kidney disease (ARPKD), by determining the relationship between cyst development and indices of renal function and cardiovascular disease. RESULTS In the LPK (n = 35), cysts appear at week 3 (1.1 +/- 0.1 mm) increasing to week 24 (2.8 +/- 2 mm). Immunostaining for nephron-specific segments indicate cysts develop predominantly from the collecting duct. Cyst formation preceded hypertension (160 +/- 22 vs. Lewis control 105 +/- 20 mm Hg systolic blood pressure (BP), n = 12) at week 6, elevated creatinine (109 +/- 63 vs. 59 +/- 6 micromol/l, n = 16) and cardiac mass (0.7 vs. 0.4% bodyweight, n = 15) at week 12, and left ventricular hypertrophy (2,898 +/- 207 vs. 1,808 +/- 192 mum, n = 14) at week 24 (all p < or = 0.05). Plasma-renin activity and angiotensin II were reduced in 10- to 12-week LPK (2.2 +/- 2.9 vs. Lewis 11.9 +/- 4.9 ng/ml/h, and 25.0 +/- 19.1 vs. 94.9 +/- 64.4 pg/ml, respectively, n = 26, p < or = 0.05). Ganglionic blockade (hexamethonium 3.3 mg/kg) significantly reduced mean BP in the LPK (52 vs. Lewis 4%, n = 9, p < or = 0.05). CONCLUSION Cyst formation is a key event in the genesis of hypertension while the sympathetic nervous system is important in the maintenance of hypertension in this model of ARPKD.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal
- Biomarkers/metabolism
- Creatinine/blood
- Disease Models, Animal
- Female
- Hypertension, Renal/etiology
- Hypertension, Renal/genetics
- Hypertension, Renal/pathology
- Hypertrophy, Left Ventricular/etiology
- Hypertrophy, Left Ventricular/genetics
- Hypertrophy, Left Ventricular/pathology
- Immunohistochemistry
- Kidney Cortex/innervation
- Kidney Cortex/metabolism
- Kidney Cortex/pathology
- Kidney Medulla/innervation
- Kidney Medulla/metabolism
- Kidney Medulla/pathology
- Kidney Tubules, Distal/innervation
- Kidney Tubules, Distal/metabolism
- Kidney Tubules, Distal/pathology
- Kidney Tubules, Proximal/innervation
- Kidney Tubules, Proximal/metabolism
- Kidney Tubules, Proximal/pathology
- Liver/metabolism
- Liver/pathology
- Male
- Myocardium/metabolism
- Myocardium/pathology
- Polycystic Kidney, Autosomal Recessive/complications
- Polycystic Kidney, Autosomal Recessive/genetics
- Polycystic Kidney, Autosomal Recessive/pathology
- Predictive Value of Tests
- Rats
- Rats, Inbred Lew
- Rats, Mutant Strains
- Renin-Angiotensin System/physiology
- Sympathetic Nervous System/drug effects
- Sympathetic Nervous System/physiology
- Sympatholytics/pharmacology
- Time Factors
- Urea/blood
Collapse
Affiliation(s)
- Jacqueline K Phillips
- Division of Health Sciences, School of Veterinary and Biomedical Science, Murdoch University, Perth, Australia.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Gunay-Aygun M, Avner ED, Bacallo RL, Choyke PL, Flynn JT, Germino GG, Guay-Woodford L, Harris P, Heller T, Ingelfinger J, Kaskel F, Kleta R, LaRusso NF, Mohan P, Pazour GJ, Shneider BL, Torres VE, Wilson P, Zak C, Zhou J, Gahl WA. Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis: summary statement of a first National Institutes of Health/Office of Rare Diseases conference. J Pediatr 2006; 149:159-64. [PMID: 16887426 PMCID: PMC2918414 DOI: 10.1016/j.jpeds.2006.03.014] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/21/2005] [Revised: 01/30/2006] [Accepted: 03/09/2006] [Indexed: 12/14/2022]
Abstract
Researchers and clinicians with expertise in autosomal recessive polycystic kidney disease and congenital hepatic fibrosis (ARPKD/CHF) and related fields met on May 5-6, 2005, on the National Institutes of Health (NIH) campus for a 1.5-day symposium sponsored by the NIH Office of Rare Diseases, the National Human Genome Research Institute (NHGRI), and in part by the ARPKD/CHF Alliance. The meeting addressed the present status and the future of ARPKD/CHF research.
Collapse
Affiliation(s)
- Meral Gunay-Aygun
- National Human Genome Research Institute, the Molecular Imaging Program, National Cancer Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-1851, USA.
| | - Ellis D. Avner
- National Human Genome Research Institute, the Molecular Imaging Program, National Cancer Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, Pediatric Nephrology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, Internal Medicine, Nephrology, Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, Pediatric Nephrology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, New York, NY, Internal Medicine, Nephrology, Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, Internal Medicine, Nephrology and Gastroenterology, Mayo Clinic, Rochester, MN, Pediatric Nephrology, Mass-General Hospital for Children at Massachusetts General Hospital, Harvard Medical School and the Autosomal Recessive Polycystic Kidney Disease/Congenital Hepatic Fibrosis Alliance and the Department of Internal Medicine, Harvard Institutes of Medicine, Boston, MA, Pediatric Gastroenterology, Children's National Medical Center, The George Washington University, Washington, DC, the Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, the Departments of Pediatric Hepatology and Internal Medicine, Nephrology, Mount Sinai School of Medicine, The Mount Sinai Hospital, NY
| | - Robert L. Bacallo
- National Human Genome Research Institute, the Molecular Imaging Program, National Cancer Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, Pediatric Nephrology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, Internal Medicine, Nephrology, Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, Pediatric Nephrology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, New York, NY, Internal Medicine, Nephrology, Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, Internal Medicine, Nephrology and Gastroenterology, Mayo Clinic, Rochester, MN, Pediatric Nephrology, Mass-General Hospital for Children at Massachusetts General Hospital, Harvard Medical School and the Autosomal Recessive Polycystic Kidney Disease/Congenital Hepatic Fibrosis Alliance and the Department of Internal Medicine, Harvard Institutes of Medicine, Boston, MA, Pediatric Gastroenterology, Children's National Medical Center, The George Washington University, Washington, DC, the Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, the Departments of Pediatric Hepatology and Internal Medicine, Nephrology, Mount Sinai School of Medicine, The Mount Sinai Hospital, NY
| | - Peter L. Choyke
- National Human Genome Research Institute, the Molecular Imaging Program, National Cancer Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, Pediatric Nephrology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, Internal Medicine, Nephrology, Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, Pediatric Nephrology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, New York, NY, Internal Medicine, Nephrology, Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, Internal Medicine, Nephrology and Gastroenterology, Mayo Clinic, Rochester, MN, Pediatric Nephrology, Mass-General Hospital for Children at Massachusetts General Hospital, Harvard Medical School and the Autosomal Recessive Polycystic Kidney Disease/Congenital Hepatic Fibrosis Alliance and the Department of Internal Medicine, Harvard Institutes of Medicine, Boston, MA, Pediatric Gastroenterology, Children's National Medical Center, The George Washington University, Washington, DC, the Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, the Departments of Pediatric Hepatology and Internal Medicine, Nephrology, Mount Sinai School of Medicine, The Mount Sinai Hospital, NY
| | - Joseph T. Flynn
- National Human Genome Research Institute, the Molecular Imaging Program, National Cancer Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, Pediatric Nephrology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, Internal Medicine, Nephrology, Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, Pediatric Nephrology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, New York, NY, Internal Medicine, Nephrology, Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, Internal Medicine, Nephrology and Gastroenterology, Mayo Clinic, Rochester, MN, Pediatric Nephrology, Mass-General Hospital for Children at Massachusetts General Hospital, Harvard Medical School and the Autosomal Recessive Polycystic Kidney Disease/Congenital Hepatic Fibrosis Alliance and the Department of Internal Medicine, Harvard Institutes of Medicine, Boston, MA, Pediatric Gastroenterology, Children's National Medical Center, The George Washington University, Washington, DC, the Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, the Departments of Pediatric Hepatology and Internal Medicine, Nephrology, Mount Sinai School of Medicine, The Mount Sinai Hospital, NY
| | - Gregory G. Germino
- National Human Genome Research Institute, the Molecular Imaging Program, National Cancer Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, Pediatric Nephrology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, Internal Medicine, Nephrology, Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, Pediatric Nephrology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, New York, NY, Internal Medicine, Nephrology, Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, Internal Medicine, Nephrology and Gastroenterology, Mayo Clinic, Rochester, MN, Pediatric Nephrology, Mass-General Hospital for Children at Massachusetts General Hospital, Harvard Medical School and the Autosomal Recessive Polycystic Kidney Disease/Congenital Hepatic Fibrosis Alliance and the Department of Internal Medicine, Harvard Institutes of Medicine, Boston, MA, Pediatric Gastroenterology, Children's National Medical Center, The George Washington University, Washington, DC, the Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, the Departments of Pediatric Hepatology and Internal Medicine, Nephrology, Mount Sinai School of Medicine, The Mount Sinai Hospital, NY
| | - Lisa Guay-Woodford
- National Human Genome Research Institute, the Molecular Imaging Program, National Cancer Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, Pediatric Nephrology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, Internal Medicine, Nephrology, Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, Pediatric Nephrology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, New York, NY, Internal Medicine, Nephrology, Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, Internal Medicine, Nephrology and Gastroenterology, Mayo Clinic, Rochester, MN, Pediatric Nephrology, Mass-General Hospital for Children at Massachusetts General Hospital, Harvard Medical School and the Autosomal Recessive Polycystic Kidney Disease/Congenital Hepatic Fibrosis Alliance and the Department of Internal Medicine, Harvard Institutes of Medicine, Boston, MA, Pediatric Gastroenterology, Children's National Medical Center, The George Washington University, Washington, DC, the Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, the Departments of Pediatric Hepatology and Internal Medicine, Nephrology, Mount Sinai School of Medicine, The Mount Sinai Hospital, NY
| | - Peter Harris
- National Human Genome Research Institute, the Molecular Imaging Program, National Cancer Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, Pediatric Nephrology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, Internal Medicine, Nephrology, Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, Pediatric Nephrology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, New York, NY, Internal Medicine, Nephrology, Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, Internal Medicine, Nephrology and Gastroenterology, Mayo Clinic, Rochester, MN, Pediatric Nephrology, Mass-General Hospital for Children at Massachusetts General Hospital, Harvard Medical School and the Autosomal Recessive Polycystic Kidney Disease/Congenital Hepatic Fibrosis Alliance and the Department of Internal Medicine, Harvard Institutes of Medicine, Boston, MA, Pediatric Gastroenterology, Children's National Medical Center, The George Washington University, Washington, DC, the Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, the Departments of Pediatric Hepatology and Internal Medicine, Nephrology, Mount Sinai School of Medicine, The Mount Sinai Hospital, NY
| | - Theo Heller
- National Human Genome Research Institute, the Molecular Imaging Program, National Cancer Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, Pediatric Nephrology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, Internal Medicine, Nephrology, Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, Pediatric Nephrology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, New York, NY, Internal Medicine, Nephrology, Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, Internal Medicine, Nephrology and Gastroenterology, Mayo Clinic, Rochester, MN, Pediatric Nephrology, Mass-General Hospital for Children at Massachusetts General Hospital, Harvard Medical School and the Autosomal Recessive Polycystic Kidney Disease/Congenital Hepatic Fibrosis Alliance and the Department of Internal Medicine, Harvard Institutes of Medicine, Boston, MA, Pediatric Gastroenterology, Children's National Medical Center, The George Washington University, Washington, DC, the Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, the Departments of Pediatric Hepatology and Internal Medicine, Nephrology, Mount Sinai School of Medicine, The Mount Sinai Hospital, NY
| | - Julie Ingelfinger
- National Human Genome Research Institute, the Molecular Imaging Program, National Cancer Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, Pediatric Nephrology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, Internal Medicine, Nephrology, Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, Pediatric Nephrology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, New York, NY, Internal Medicine, Nephrology, Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, Internal Medicine, Nephrology and Gastroenterology, Mayo Clinic, Rochester, MN, Pediatric Nephrology, Mass-General Hospital for Children at Massachusetts General Hospital, Harvard Medical School and the Autosomal Recessive Polycystic Kidney Disease/Congenital Hepatic Fibrosis Alliance and the Department of Internal Medicine, Harvard Institutes of Medicine, Boston, MA, Pediatric Gastroenterology, Children's National Medical Center, The George Washington University, Washington, DC, the Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, the Departments of Pediatric Hepatology and Internal Medicine, Nephrology, Mount Sinai School of Medicine, The Mount Sinai Hospital, NY
| | - Frederick Kaskel
- National Human Genome Research Institute, the Molecular Imaging Program, National Cancer Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, Pediatric Nephrology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, Internal Medicine, Nephrology, Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, Pediatric Nephrology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, New York, NY, Internal Medicine, Nephrology, Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, Internal Medicine, Nephrology and Gastroenterology, Mayo Clinic, Rochester, MN, Pediatric Nephrology, Mass-General Hospital for Children at Massachusetts General Hospital, Harvard Medical School and the Autosomal Recessive Polycystic Kidney Disease/Congenital Hepatic Fibrosis Alliance and the Department of Internal Medicine, Harvard Institutes of Medicine, Boston, MA, Pediatric Gastroenterology, Children's National Medical Center, The George Washington University, Washington, DC, the Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, the Departments of Pediatric Hepatology and Internal Medicine, Nephrology, Mount Sinai School of Medicine, The Mount Sinai Hospital, NY
| | - Robert Kleta
- National Human Genome Research Institute, the Molecular Imaging Program, National Cancer Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, Pediatric Nephrology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, Internal Medicine, Nephrology, Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, Pediatric Nephrology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, New York, NY, Internal Medicine, Nephrology, Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, Internal Medicine, Nephrology and Gastroenterology, Mayo Clinic, Rochester, MN, Pediatric Nephrology, Mass-General Hospital for Children at Massachusetts General Hospital, Harvard Medical School and the Autosomal Recessive Polycystic Kidney Disease/Congenital Hepatic Fibrosis Alliance and the Department of Internal Medicine, Harvard Institutes of Medicine, Boston, MA, Pediatric Gastroenterology, Children's National Medical Center, The George Washington University, Washington, DC, the Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, the Departments of Pediatric Hepatology and Internal Medicine, Nephrology, Mount Sinai School of Medicine, The Mount Sinai Hospital, NY
| | - Nicholas F. LaRusso
- National Human Genome Research Institute, the Molecular Imaging Program, National Cancer Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, Pediatric Nephrology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, Internal Medicine, Nephrology, Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, Pediatric Nephrology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, New York, NY, Internal Medicine, Nephrology, Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, Internal Medicine, Nephrology and Gastroenterology, Mayo Clinic, Rochester, MN, Pediatric Nephrology, Mass-General Hospital for Children at Massachusetts General Hospital, Harvard Medical School and the Autosomal Recessive Polycystic Kidney Disease/Congenital Hepatic Fibrosis Alliance and the Department of Internal Medicine, Harvard Institutes of Medicine, Boston, MA, Pediatric Gastroenterology, Children's National Medical Center, The George Washington University, Washington, DC, the Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, the Departments of Pediatric Hepatology and Internal Medicine, Nephrology, Mount Sinai School of Medicine, The Mount Sinai Hospital, NY
| | - Parvathi Mohan
- National Human Genome Research Institute, the Molecular Imaging Program, National Cancer Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, Pediatric Nephrology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, Internal Medicine, Nephrology, Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, Pediatric Nephrology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, New York, NY, Internal Medicine, Nephrology, Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, Internal Medicine, Nephrology and Gastroenterology, Mayo Clinic, Rochester, MN, Pediatric Nephrology, Mass-General Hospital for Children at Massachusetts General Hospital, Harvard Medical School and the Autosomal Recessive Polycystic Kidney Disease/Congenital Hepatic Fibrosis Alliance and the Department of Internal Medicine, Harvard Institutes of Medicine, Boston, MA, Pediatric Gastroenterology, Children's National Medical Center, The George Washington University, Washington, DC, the Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, the Departments of Pediatric Hepatology and Internal Medicine, Nephrology, Mount Sinai School of Medicine, The Mount Sinai Hospital, NY
| | - Gregory J. Pazour
- National Human Genome Research Institute, the Molecular Imaging Program, National Cancer Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, Pediatric Nephrology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, Internal Medicine, Nephrology, Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, Pediatric Nephrology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, New York, NY, Internal Medicine, Nephrology, Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, Internal Medicine, Nephrology and Gastroenterology, Mayo Clinic, Rochester, MN, Pediatric Nephrology, Mass-General Hospital for Children at Massachusetts General Hospital, Harvard Medical School and the Autosomal Recessive Polycystic Kidney Disease/Congenital Hepatic Fibrosis Alliance and the Department of Internal Medicine, Harvard Institutes of Medicine, Boston, MA, Pediatric Gastroenterology, Children's National Medical Center, The George Washington University, Washington, DC, the Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, the Departments of Pediatric Hepatology and Internal Medicine, Nephrology, Mount Sinai School of Medicine, The Mount Sinai Hospital, NY
| | - Benjamin L. Shneider
- National Human Genome Research Institute, the Molecular Imaging Program, National Cancer Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, Pediatric Nephrology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, Internal Medicine, Nephrology, Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, Pediatric Nephrology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, New York, NY, Internal Medicine, Nephrology, Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, Internal Medicine, Nephrology and Gastroenterology, Mayo Clinic, Rochester, MN, Pediatric Nephrology, Mass-General Hospital for Children at Massachusetts General Hospital, Harvard Medical School and the Autosomal Recessive Polycystic Kidney Disease/Congenital Hepatic Fibrosis Alliance and the Department of Internal Medicine, Harvard Institutes of Medicine, Boston, MA, Pediatric Gastroenterology, Children's National Medical Center, The George Washington University, Washington, DC, the Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, the Departments of Pediatric Hepatology and Internal Medicine, Nephrology, Mount Sinai School of Medicine, The Mount Sinai Hospital, NY
| | - Vicente E. Torres
- National Human Genome Research Institute, the Molecular Imaging Program, National Cancer Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, Pediatric Nephrology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, Internal Medicine, Nephrology, Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, Pediatric Nephrology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, New York, NY, Internal Medicine, Nephrology, Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, Internal Medicine, Nephrology and Gastroenterology, Mayo Clinic, Rochester, MN, Pediatric Nephrology, Mass-General Hospital for Children at Massachusetts General Hospital, Harvard Medical School and the Autosomal Recessive Polycystic Kidney Disease/Congenital Hepatic Fibrosis Alliance and the Department of Internal Medicine, Harvard Institutes of Medicine, Boston, MA, Pediatric Gastroenterology, Children's National Medical Center, The George Washington University, Washington, DC, the Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, the Departments of Pediatric Hepatology and Internal Medicine, Nephrology, Mount Sinai School of Medicine, The Mount Sinai Hospital, NY
| | - Patricia Wilson
- National Human Genome Research Institute, the Molecular Imaging Program, National Cancer Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, Pediatric Nephrology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, Internal Medicine, Nephrology, Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, Pediatric Nephrology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, New York, NY, Internal Medicine, Nephrology, Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, Internal Medicine, Nephrology and Gastroenterology, Mayo Clinic, Rochester, MN, Pediatric Nephrology, Mass-General Hospital for Children at Massachusetts General Hospital, Harvard Medical School and the Autosomal Recessive Polycystic Kidney Disease/Congenital Hepatic Fibrosis Alliance and the Department of Internal Medicine, Harvard Institutes of Medicine, Boston, MA, Pediatric Gastroenterology, Children's National Medical Center, The George Washington University, Washington, DC, the Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, the Departments of Pediatric Hepatology and Internal Medicine, Nephrology, Mount Sinai School of Medicine, The Mount Sinai Hospital, NY
| | - Colleen Zak
- National Human Genome Research Institute, the Molecular Imaging Program, National Cancer Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, Pediatric Nephrology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, Internal Medicine, Nephrology, Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, Pediatric Nephrology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, New York, NY, Internal Medicine, Nephrology, Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, Internal Medicine, Nephrology and Gastroenterology, Mayo Clinic, Rochester, MN, Pediatric Nephrology, Mass-General Hospital for Children at Massachusetts General Hospital, Harvard Medical School and the Autosomal Recessive Polycystic Kidney Disease/Congenital Hepatic Fibrosis Alliance and the Department of Internal Medicine, Harvard Institutes of Medicine, Boston, MA, Pediatric Gastroenterology, Children's National Medical Center, The George Washington University, Washington, DC, the Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, the Departments of Pediatric Hepatology and Internal Medicine, Nephrology, Mount Sinai School of Medicine, The Mount Sinai Hospital, NY
| | - Jing Zhou
- National Human Genome Research Institute, the Molecular Imaging Program, National Cancer Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, Pediatric Nephrology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, Internal Medicine, Nephrology, Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, Pediatric Nephrology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, New York, NY, Internal Medicine, Nephrology, Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, Internal Medicine, Nephrology and Gastroenterology, Mayo Clinic, Rochester, MN, Pediatric Nephrology, Mass-General Hospital for Children at Massachusetts General Hospital, Harvard Medical School and the Autosomal Recessive Polycystic Kidney Disease/Congenital Hepatic Fibrosis Alliance and the Department of Internal Medicine, Harvard Institutes of Medicine, Boston, MA, Pediatric Gastroenterology, Children's National Medical Center, The George Washington University, Washington, DC, the Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, the Departments of Pediatric Hepatology and Internal Medicine, Nephrology, Mount Sinai School of Medicine, The Mount Sinai Hospital, NY
| | - William A. Gahl
- National Human Genome Research Institute, the Molecular Imaging Program, National Cancer Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, Pediatric Nephrology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, Internal Medicine, Nephrology, Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, Pediatric Nephrology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, New York, NY, Internal Medicine, Nephrology, Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, Internal Medicine, Nephrology and Gastroenterology, Mayo Clinic, Rochester, MN, Pediatric Nephrology, Mass-General Hospital for Children at Massachusetts General Hospital, Harvard Medical School and the Autosomal Recessive Polycystic Kidney Disease/Congenital Hepatic Fibrosis Alliance and the Department of Internal Medicine, Harvard Institutes of Medicine, Boston, MA, Pediatric Gastroenterology, Children's National Medical Center, The George Washington University, Washington, DC, the Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, the Departments of Pediatric Hepatology and Internal Medicine, Nephrology, Mount Sinai School of Medicine, The Mount Sinai Hospital, NY
| |
Collapse
|
43
|
Abstract
The hepatic fibrocystic diseases present with variable intrahepatic biliary abnormalities, which range from portal tract enlargement and fibrosis to cystic formations. They may present as autosomal recessive or dominant polycystic kidney diseases, with associated dilatation of the renal collecting system, or as incompletely characterized cystic diseases. Symptoms from the liver disease often result from complications of fibrosis or dilated ducts/cyst (sludge, lithiasis, infection). The treatment is supportive, with careful attention to associated renal disease. Liver transplantation is an option in selected patients.
Collapse
Affiliation(s)
- Nanda Kerkar
- Department of Pediatrics, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, NY 10029, USA
| | | | | |
Collapse
|
44
|
Abstract
Hepatic complications occur in a significant proportion of children with autosomal recessive polycystic kidney disease (ARPKD). PKHD1/fibrocystin, the defective gene in ARPKD, is expressed in the cilia of bile duct epithelium and leads to abnormalities in the rubric of the ductal plate malformation. Portal hypertension and biliary disease are the major liver problems seen in ARPKD. Complete blood counting, physical examination, ultrasonography and magnetic resonance (MR) cholangiography are indicated as screening procedures for hepatic disease in ARPKD. Medical and surgical interventions are potentially indicated for children with portal hypertension and/or biliary disease. A high index of suspicion for the diagnosis of cholangitis needs to be maintained in children with biliary disease. The implications of hepatic disease need to be considered in the decision-making regarding renal transplantation in ARPKD.
Collapse
|
45
|
|
46
|
Consugar MB, Anderson SA, Rossetti S, Pankratz VS, Ward CJ, Torra R, Coto E, El-Youssef M, Kantarci S, Utsch B, Hildebrandt F, Sweeney WE, Avner ED, Torres VE, Cunningham JM, Harris PC. Haplotype analysis improves molecular diagnostics of autosomal recessive polycystic kidney disease. Am J Kidney Dis 2005; 45:77-87. [PMID: 15696446 DOI: 10.1053/j.ajkd.2004.09.009] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND Autosomal recessive polycystic kidney disease (ARPKD) is characterized by wide phenotypic variability, ranging from in utero detection with enlarged, echogenic kidneys to an adult presentation with congenital hepatic fibrosis. The ARPKD gene, PKHD1 , covers about 470 kb of DNA (67 exons), and mutation studies have found marked allelic heterogeneity with a high level of novel missense changes and neutral polymorphisms. To improve the prospects for molecular diagnostics and to study the origin of some relatively common mutations, the authors have developed a strategy for improved ARPKD haplotyping. METHODS A protocol of multiplex PCR and fluorescence genotyping in a single capillary has been developed to assay 7 highly informative simple sequence repeat (SSR) markers that are intragenic or closely flanking PKHD1. RESULTS Examples in which haplotype analysis, used in combination with mutation screening, improved the utility of molecular diagnostics, especially in families in which just a single PKHD1 mutation has been identified, are illustrated. The new markers also allow screening for larger DNA deletions, detecting unknown consanguinity and exploring the disease mechanism. Analysis of 8 recurring mutations has shown likely common haplotypes for each, and the divergence from the ancestral haplotype, by recombination, can be used to trace the history of the mutation. The common mutation, T36M, was found to have a single European origin, about 1,225 years ago. CONCLUSION Improved haplotype analysis of ARPKD complements mutation-based diagnostics and helps trace the history of common PKHD1 mutations.
Collapse
Affiliation(s)
- Mark B Consugar
- Division of Nephrology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Bergmann C, Senderek J, Windelen E, Küpper F, Middeldorf I, Schneider F, Dornia C, Rudnik-Schöneborn S, Konrad M, Schmitt CP, Seeman T, Neuhaus TJ, Vester U, Kirfel J, Büttner R, Zerres K. Clinical consequences of PKHD1 mutations in 164 patients with autosomal-recessive polycystic kidney disease (ARPKD). Kidney Int 2005; 67:829-48. [PMID: 15698423 DOI: 10.1111/j.1523-1755.2005.00148.x] [Citation(s) in RCA: 187] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND ARPKD is associated with mutations in the PKHD1 gene on chromosome 6p12. Most cases manifest peri-/neonatally with a high mortality rate in the first month of life while the clinical spectrum of surviving patients is much more variable than generally perceived. METHODS We examined the clinical course of 164 neonatal survivors (126 unrelated families) over a mean observation period of 6 years (range 0 to 35 years). PKHD1 mutation screening was done by denaturing high-performance liquid chromatography (DHPLC) for the 66 exons encoding the 4074 aa fibrocystin/polyductin protein. RESULTS AND CONCLUSION This is the first study that reports the long-term outcome of ARPKD patients with defined PKHD1 mutations. The 1- and 10-year survival rates were 85% and 82%, respectively. Chronic renal failure was first detected at a mean age of 4 years. Actuarial renal survival rates [end point defined as start of dialysis/renal transplantation (RTX) or by death due to end-stage renal disease (ESRD)] were 86% at 5 years, 71% at 10 years, and 42% at 20 years. All but six patients (92%) had a kidney length above or on the 97th centile for age. About 75% of the study population developed systemic hypertension. Sequelae of congenital hepatic fibrosis and portal hypertension developed in 44% of patients and were related with age. Positive correlations could further be demonstrated between renal and hepatobiliary-related morbidity suggesting uniform disease progression rather than organ-specific patterns. PKHD1 mutation analysis revealed 193 mutations (70 novel ones; 77% nonconservative missense mutations). No patient carried two truncating mutations corroborating that one missense mutation is indispensable for survival of newborns. We attempted to set up genotype-phenotype correlations and to categorize missense mutations. In 96% of families we identified at least one mutated PKHD1 allele (overall detection rate 76.6%) indicating that PKHD1 mutation screening is a powerful diagnostic tool in patients suspected with ARPKD.
Collapse
Affiliation(s)
- Carsten Bergmann
- Department of Human Genetics, Aachen University, Aachen, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Abstract
Autosomal recessive polycystic kidney disease (ARPKD) is a severe form of inherited childhood nephropathy ( approximately 1:20,000 live births) characterized by fusiform dilatation of collecting ducts and congenital hepatic fibrosis. Up to 30% die as neonates due to respiratory insufficiency and the majority of surviving infants develop hypertension. Progression to end stage renal disease occurs in 20-45% of cases within 15 years but a proportion maintain renal function into adulthood where complications of liver disease predominate. The ARPKD disease gene, PKHD1, has recently been identified through analysis of an orthologous animal model, the PCK rat. PKHD1 is a large gene ( approximately 470 kb) with 67 exons from which multiple transcripts may be generated by alternative splicing. It is highly expressed in kidney, with lower levels in liver and pancreas. The ARPKD protein, fibrocystin (4074 aa and 447 kDa), is predicted to be an integral membrane, receptor-like protein containing multiple copies of an Ig-like domain (TIG). Fibrocystin is localized to the branching ureteric bud, collecting and biliary ducts, consistent with the disease phenotype, and often absent from ARPKD tissue. In common with other PKD-related proteins, fibrocystin is localized to the primary cilia of renal epithelial cells, reinforcing the link between ciliary dysfunction and cyst development. Screens of PKHD1 have revealed 119 different mutations of various types spread throughout the gene. Several ancestral changes have been described, some localized to specific geographic populations. The majority of patients are compound heterozygotes and preliminary genotype/phenotype studies associate two truncating mutations with severe disease. The complexities of PKHD1, marked allelic heterogeneity and high level of missense changes complicate gene-based diagnostics.
Collapse
Affiliation(s)
- Peter C Harris
- Division of Nephrology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
| | | |
Collapse
|
49
|
Furu L, Onuchic LF, Gharavi A, Hou X, Esquivel EL, Nagasawa Y, Bergmann C, Senderek J, Avner E, Zerres K, Germino GG, Guay-Woodford LM, Somlo S. Milder presentation of recessive polycystic kidney disease requires presence of amino acid substitution mutations. J Am Soc Nephrol 2003; 14:2004-14. [PMID: 12874454 DOI: 10.1097/01.asn.0000078805.87038.05] [Citation(s) in RCA: 90] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Autosomal recessive polycystic kidney disease (ARPKD; MIM 263200) is a hereditary and severe form of polycystic disease affecting the kidneys and biliary tract with an estimated incidence of 1 in 20,000 live births. The clinical spectrum is widely variable: up to 50% of affected neonates die shortly after birth, whereas others survive to adulthood. Mutations at a single locus, polycystic kidney and hepatic disease 1 (PKHD1), are responsible for all typical forms of ARPKD. Mutation detection was performed in PKHD1 by DHPLC in 85 affected, unrelated individuals. Seventy-four amplicons were amplified and analyzed from the PKHD1 genomic locus. Sequence variants were considered pathogenic when they were not observed in 160 control individuals (320 chromosomes). For purposes of genotype-phenotype comparisons, families were stratified by clinical presentation into two groups: the severe perinatal group, in which at least one affected child presented with perinatal disease and neonatal demise, and the less severe, nonperinatal group, in which none of the affected children died in the neonatal period. Forty-one mutations were found in 55 affected disease chromosomes; 32 of these mutations have not been reported previously. Mutations were distributed throughout the portions of gene encoding the predicted extracellular portion of the protein product. The most commonly encountered mutation, T36M, was found in 8 of 55 disease chromosomes. Amino acid substitutions were found to be more commonly associated with a nonlethal presentation, whereas chain terminating mutations were more commonly associated with neonatal demise (chi(2) = 11.54, P = 0.003). All patients who survive the neonatal period have at least one amino acid substitution mutation, suggesting that such substitutions produce milder disease through production of partially functional protein products. The nature of the germline mutations in ARPKD plays a significant role in determining clinical outcome.
Collapse
Affiliation(s)
- Laszlo Furu
- Departments of Internal Medicine and Genetics, Yale University School of Medicine, New Haven, Connecticut, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Guay-Woodford LM, Desmond RA. Autosomal recessive polycystic kidney disease: the clinical experience in North America. Pediatrics 2003; 111:1072-80. [PMID: 12728091 DOI: 10.1542/peds.111.5.1072] [Citation(s) in RCA: 232] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
OBJECTIVE We designed a longitudinal clinical database for autosomal recessive polycystic kidney disease (ARPKD), recruited patients from pediatric nephrology centers in the United States and Canada, and examined their clinical morbidities and survival characteristics. We initially targeted enrollment to children who were born and diagnosed after January 1, 1990, so as to capture a cohort that is representative of ARPKD patients born in the last decade. When a significant number of older ARPKD patients were also referred, we extended our database to include all patients who met our inclusion criteria, thereby allowing direct comparisons between a long-term survivor subset and a cohort that included both neonatal survivors and nonsurvivors. DESIGN Patient entry into our database required either compatible histopathology or ultrasonographic evidence of enlarged, echogenic kidneys and the presence of at least 1 of the following additional criteria: a) biopsy-proven ARPKD in a sibling; b) biliary fibrosis based on either clinical or histopathologic evidence; c) no sonographic evidence of renal cysts in the parents (parents must be >30 years of age); or d) parental consanguinity, eg, first-cousin marriage. Clinical questionnaires (primary data form and follow-up data form) were developed to collect initial patient data and follow-up data at yearly intervals. RESULTS Thirty-four centers provided clinical information for 254 patients and of these, 209 had sufficient data for analyses. When stratified by date of birth, 166 (79.4%) were born on or after January 1, 1990 (younger cohort) and 43 children (20.6%) were born before 1990 (older cohort). The gender distribution was equal in both cohorts. The median age at diagnosis was significantly later in the older cohort and no deaths were reported among these patients, suggesting that this group is biased toward long-term survivors. In the younger cohort, 74.7% of the patients are alive, with a median age of 5.4 years. In this group, 40.5% of patients required ventilation and 11.6% developed chronic lung disease. Hypertension was a common, but not universal finding in both cohorts. The relative risk for developing hypertension was higher in the older cohort, but the median age at diagnosis was significantly earlier in the younger cohort. Chronic renal insufficiency (CRI) was reported in approximately 40% of patients with no significant difference in the relative risk between age groups. However, in the younger cohort, the median age at diagnosis was significantly earlier and the age of diagnosis of CRI and hypertension were significantly correlated. Clinically significant morbidities related to periportal fibrosis were more common in the older cohort. There was a trend toward increasing frequency of portal hypertension with age in both cohorts. Portal hypertension was not significantly correlated with either systemic hypertension or CRI. CONCLUSIONS The ARPKD Clinical Database represents the largest single cohort of ARPKD patients collected to date. Our initial data analysis provides several new clinical insights. First, in our subset of long-term survivors, ARPKD has a slower rate of disease progression, as assessed by age of ARPKD diagnosis, as well as age of diagnosis of clinical morbidities. Second, neonatal ventilation was strongly predictive of mortality as well as an earlier age of diagnosis in those who developed hypertension or chronic renal insufficiency. However, for infants who survive the perinatal period, the long-term prognosis for patient survival is much better than generally perceived. Third, although systemic hypertension and CRI were significantly correlated with respect to age of diagnosis, similar relationships with portal hypertension were not evident, suggesting that disease progression may have organ-specific patterns. Fourth, only a subset of patients may be at risk for developing clinically significant manifestations of periportal fibrosis. Based on these observations, the next challenges will be to determine how various factors, such as specific mutations in the ARPKD gene, PKHD1(polycystic kidney and hepatic disease 1), variations in modifying gene loci, modulation by as yet unspecified environmental factors, and/or gene-environment interactions contribute to the marked variability in survival and disease expression observed among ARPKD patients.
Collapse
Affiliation(s)
- Lisa M Guay-Woodford
- Division of Genetic and Translational Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.
| | | |
Collapse
|